Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Multiple Sclerosis

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 687 articles:
HTML format



Single Articles


    March 2024
  1. CAMPAGNA MP, Havrdova EK, Horakova D, Izquierdo G, et al
    No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registry.
    Mult Scler. 2024 Mar 21:13524585241240406. doi: 10.1177/13524585241240406.
    PubMed     Abstract available


  2. HJALGRIM H, Rostgaard K
    Infectious mononucleosis and risk of multiple sclerosis: Proxy or culprit?
    Mult Scler. 2024 Mar 21:13524585241237708. doi: 10.1177/13524585241237708.
    PubMed    


  3. GOLDACRE R
    Risk of multiple sclerosis in individuals with infectious mononucleosis: a national population-based cohort study using hospital records in England, 2003-2023.
    Mult Scler. 2024 Mar 21:13524585241237707. doi: 10.1177/13524585241237707.
    PubMed     Abstract available


  4. JOHNSSON M, Stenberg YT, Farman HH, Blennow K, et al
    Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
    Mult Scler. 2024 Mar 13:13524585241237388. doi: 10.1177/13524585241237388.
    PubMed     Abstract available


  5. NAKAMURA K, Sun Z, Hara-Cleaver C, Bodhinathan K, et al
    Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Mult Scler. 2024 Mar 12:13524585241235055. doi: 10.1177/13524585241235055.
    PubMed     Abstract available


  6. EHLING R, Seebacher B, Brenneis C
    Letter to the editor: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Mar 11:13524585241234789. doi: 10.1177/13524585241234789.
    PubMed    


  7. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
    Expert opinion on the use of contraception in people with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
    PubMed     Abstract available


  8. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
    PubMed     Abstract available


  9. KUBICKI K, Stefoski D
    Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
    Mult Scler. 2024 Mar 8:13524585241235539. doi: 10.1177/13524585241235539.
    PubMed     Abstract available


  10. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
    PubMed     Abstract available


  11. GIULIANI G, Zilli C, Caramia F, Di Piero V, et al
    SUNCT syndrome secondary to multiple sclerosis: Not only trigeminal neuralgia.
    Mult Scler. 2024 Mar 1:13524585241235535. doi: 10.1177/13524585241235535.
    PubMed     Abstract available


    February 2024
  12. AFZAL RM, Romme Christensen J, Gynthersen RMM, Lebech AM, et al
    Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report.
    Mult Scler. 2024 Feb 29:13524585241235542. doi: 10.1177/13524585241235542.
    PubMed     Abstract available


  13. KARI S, Bucciarelli F, Angles T, Oster AC, et al
    Increased levels of circulating soluble CD226 in multiple sclerosis.
    Mult Scler. 2024 Feb 29:13524585241234489. doi: 10.1177/13524585241234489.
    PubMed     Abstract available


  14. HEESEN C, Luhmann D
    Reply: Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2024 Feb 29:13524585241234777. doi: 10.1177/13524585241234777.
    PubMed    


  15. LIM TRU, Kumaran SP, Suthiphosuwan S, Espiritu AI, et al
    Limited utility of adding 3T cervical spinal cord MRI to monitor disease activity in multiple sclerosis.
    Mult Scler. 2024 Feb 28:13524585241228426. doi: 10.1177/13524585241228426.
    PubMed     Abstract available


  16. NAKKEN O, Aarseth JH, Wergeland S, Stigum H, et al
    BCG vaccination and multiple sclerosis risk: A Norwegian cohort study.
    Mult Scler. 2024 Feb 27:13524585241230440. doi: 10.1177/13524585241230440.
    PubMed     Abstract available


  17. MILLER AE
    Dissemination in time as a requirement for diagnosis of multiple sclerosis: Time for a change?
    Mult Scler. 2024 Feb 27:13524585241233999. doi: 10.1177/13524585241233999.
    PubMed     Abstract available


  18. KRIEGER SC, Sinks S, Huang F, Steverson J, et al
    The impact of social distancing measures on anti-JC virus serostatus changes before and during the COVID-19 pandemic in US patients with multiple sclerosis.
    Mult Scler. 2024 Feb 26:13524585241232274. doi: 10.1177/13524585241232274.
    PubMed     Abstract available


  19. BOAVENTURA M, Sastre-Garriga J, Rimkus CM, Rovira A, et al
    T1/T2-weighted ratio: A feasible MRI biomarker in multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241233448. doi: 10.1177/13524585241233448.
    PubMed     Abstract available


  20. EMMA C, Vesela P, Kay P, Huseyin H, et al
    Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
    Mult Scler. 2024 Feb 22:13524585241232277. doi: 10.1177/13524585241232277.
    PubMed     Abstract available


  21. ERCAN MB, Kocer B, Altiparmak T, Arslan I, et al
    Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2024 Feb 22:13524585241231655. doi: 10.1177/13524585241231655.
    PubMed    


  22. JALALEDDINI K, Bermel RA, Talente B, Weinstein D, et al
    A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241227372. doi: 10.1177/13524585241227372.
    PubMed     Abstract available


  23. ROCCA MA, D'Amore G, Valsasina P, Tedone N, et al
    2.5-Year changes of connectivity dynamism are relevant for physical and cognitive deterioration in multiple sclerosis.
    Mult Scler. 2024 Feb 19:13524585241231155. doi: 10.1177/13524585241231155.
    PubMed     Abstract available


  24. ROVARIS M, Toselli E, Mendozzi L, Di Tella S, et al
    Eye movement desensitization and reprocessing for depressed individuals with multiple sclerosis: A pilot study.
    Mult Scler. 2024 Feb 19:13524585241230236. doi: 10.1177/13524585241230236.
    PubMed     Abstract available


  25. HOANG P, Sturnieks DL, Butler A, Chaplin C, et al
    A custom-built step exergame training programme to prevent falls in people with multiple sclerosis: A multicentre randomised controlled trial.
    Mult Scler. 2024 Feb 16:13524585241229360. doi: 10.1177/13524585241229360.
    PubMed     Abstract available


  26. COLLONGUES N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, et al
    Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2024 Feb 15:13524585231223880. doi: 10.1177/13524585231223880.
    PubMed     Abstract available


  27. PATEL S, Rafferty S, Aquino L, Chadha S, et al
    VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
    Mult Scler. 2024 Feb 15:13524585241228739. doi: 10.1177/13524585241228739.
    PubMed     Abstract available


  28. KVISTAD CE, Lehmann AK, Kvistad SAS, Holmoy T, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
    Mult Scler. 2024 Feb 12:13524585241231665. doi: 10.1177/13524585241231665.
    PubMed     Abstract available


  29. MOTL RW, Russell DI, Pilutti LA, Metse AP, et al
    Drop-out, adherence, and compliance in randomized controlled trials of exercise training in multiple sclerosis: Short report.
    Mult Scler. 2024 Feb 9:13524585241229332. doi: 10.1177/13524585241229332.
    PubMed     Abstract available


  30. BELLUCCI G, Buscarinu MC, Renie R, Rinaldi V, et al
    Disentangling multiple sclerosis phenotypes through Mendelian disorders: A network approach.
    Mult Scler. 2024 Feb 9:13524585241227119. doi: 10.1177/13524585241227119.
    PubMed     Abstract available


  31. ZIAEI A, Solomon O, Casper TC, Waltz M, et al
    Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis.
    Mult Scler. 2024 Feb 9:13524585231224685. doi: 10.1177/13524585231224685.
    PubMed     Abstract available


  32. GILMARTIN CG, Hoyle N, Garjani A, Dixon T, et al
    Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis.
    Mult Scler. 2024 Feb 7:13524585231225711. doi: 10.1177/13524585231225711.
    PubMed     Abstract available


  33. MCGINLEY MP, Manouchehrinia A
    The landscape of multiple sclerosis registries: Strengths and limitations.
    Mult Scler. 2024 Feb 6:13524585241228746. doi: 10.1177/13524585241228746.
    PubMed    


  34. VUKUSIC S, Bourre B, Casey R, Deiva K, et al
    The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years-Protocol, recruitment status, and baseline characteristics.
    Mult Scler. 2024;30:216-226.
    PubMed     Abstract available


  35. GHAJARZADEH M, Fitzgerald KC, Mowry EM, Nourbakhsh B, et al
    Association between demographics, socioeconomics, and disease-related factors and the perception of stigma in people with MS.
    Mult Scler. 2024;30:238-246.
    PubMed     Abstract available


  36. SCHNEIDER R, Brand-Arzamendi K, Reynold Lim T, Lee LE, et al
    Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome.
    Mult Scler. 2024;30:156-165.
    PubMed     Abstract available


  37. LANGDON D
    Neuropsychological assessment in MS is outdated and in need for innovation: NO.
    Mult Scler. 2024;30:152-153.
    PubMed    


    January 2024
  38. NAKAMURA K, Thoomukuntla B, Bena J, Cohen JA, et al
    Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.
    Mult Scler. 2024 Jan 29:13524585231224702. doi: 10.1177/13524585231224702.
    PubMed     Abstract available


  39. SWITAL M, Drouin J, Miranda S, Bakchine S, et al
    Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Mult Scler. 2024 Jan 27:13524585231223395. doi: 10.1177/13524585231223395.
    PubMed     Abstract available


  40. MISCIOSCIA A, Treaba CA, Barletta VT, Herranz E, et al
    White matter paramagnetic rim and non-rim lesions share a periventricular gradient in multiple sclerosis: A 7-T imaging study.
    Mult Scler. 2024 Jan 27:13524585231224681. doi: 10.1177/13524585231224681.
    PubMed     Abstract available


  41. HIRT J, Janiaud P, Dublin P, Nicoletti GJ, et al
    Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
    Mult Scler. 2024 Jan 22:13524585231221938. doi: 10.1177/13524585231221938.
    PubMed     Abstract available


  42. CAMERLINGO S, Rubinstein F, Celia Ysrraelit M, Correale J, et al
    Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
    Mult Scler. 2024 Jan 21:13524585231219138. doi: 10.1177/13524585231219138.
    PubMed     Abstract available


  43. JEANTIN L, Januel E, Labauge P, Maillart E, et al
    COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Mult Scler. 2024 Jan 21:13524585231218149. doi: 10.1177/13524585231218149.
    PubMed     Abstract available


  44. TENI FS, Machado A, Fink K, Gyllensten H, et al
    Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Mult Scler. 2024 Jan 19:13524585231225929. doi: 10.1177/13524585231225929.
    PubMed     Abstract available


  45. VIDAL-JORDANA A, Sastre-Garriga J, Tintore M, Rovira A, et al
    Optic nerve topography in multiple sclerosis diagnostic criteria: Existing knowledge and future directions.
    Mult Scler. 2024 Jan 19:13524585231225848. doi: 10.1177/13524585231225848.
    PubMed     Abstract available


  46. TOOROP AA, Noteboom S, Steenwijk MD, Gravendeel JW, et al
    Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Mult Scler. 2024 Jan 18:13524585231225855. doi: 10.1177/13524585231225855.
    PubMed     Abstract available


  47. DAS J, Rog DJ, Middleton R, Rodgers JW, et al
    University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register.
    Mult Scler. 2024 Jan 17:13524585231221411. doi: 10.1177/13524585231221411.
    PubMed     Abstract available


  48. PORTACCIO E, Iaffaldano P
    Maternal smoking and multiple sclerosis risk in offspring: A further clue of prenatal environmental triggers.
    Mult Scler. 2024 Jan 11:13524585231224667. doi: 10.1177/13524585231224667.
    PubMed    


  49. FRAMKE E, Thygesen LC, Malmborg M, Schou M, et al
    Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark.
    Mult Scler. 2024 Jan 11:13524585231221415. doi: 10.1177/13524585231221415.
    PubMed     Abstract available


  50. MOTYL J
    Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs.
    Mult Scler. 2024 Jan 9:13524585231221409. doi: 10.1177/13524585231221409.
    PubMed    


  51. MORROW SA
    Response to letter to the editor "Advancing assessment of cognitive change in multiple sclerosis: Seeking valid and sensitive approaches beyond simple cut-offs".
    Mult Scler. 2024 Jan 9:13524585231221412. doi: 10.1177/13524585231221412.
    PubMed    


  52. VENET M, Lepine A, Maarouf A, Biotti D, et al
    Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
    Mult Scler. 2024 Jan 2:13524585231223069. doi: 10.1177/13524585231223069.
    PubMed     Abstract available


  53. VAN LAETHEM D, Denissen S, Costers L, Descamps A, et al
    The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment.
    Mult Scler. 2024;30:121-130.
    PubMed     Abstract available


  54. HUGOS CL, Joos SK, Perumean-Chaney SE, Cutter GR, et al
    Stretching is not essential for managing MS spasticity: A randomized controlled trial.
    Mult Scler. 2024;30:89-102.
    PubMed     Abstract available


  55. DE GIER M, Beckerman H, Twisk JW, Knoop H, et al
    Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.
    Mult Scler. 2024;30:71-79.
    PubMed     Abstract available


  56. WRIGHT SL, Thompson AJ
    Managing patients with late-onset neutropenia during treatment with ocrelizumab.
    Mult Scler. 2024;30:134.
    PubMed    


  57. KOCH-HENRIKSEN NI, Thygesen LC, Sorensen PS, Magyari M, et al
    Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS.
    Mult Scler. 2024;30:113-120.
    PubMed     Abstract available


    December 2023
  58. PARCIAK T, Geys L, Helme A, van der Mei I, et al
    Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force.
    Mult Scler. 2023 Dec 23:13524585231216004. doi: 10.1177/13524585231216004.
    PubMed     Abstract available


  59. DOBSON R, Holden D, Vickaryous N, Bestwick J, et al
    A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
    Mult Scler. 2023 Dec 22:13524585231215268. doi: 10.1177/13524585231215268.
    PubMed     Abstract available


  60. NAISMITH RT, Cohen JA, Bar-Or A, Comi G, et al
    Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
    Mult Scler. 2023 Dec 21:13524585231216854. doi: 10.1177/13524585231216854.
    PubMed     Abstract available


  61. TAZZA F, Schiavi S, Leveraro E, Cellerino M, et al
    Clinical and radiological correlates of apathy in multiple sclerosis.
    Mult Scler. 2023 Dec 14:13524585231217918. doi: 10.1177/13524585231217918.
    PubMed     Abstract available


  62. DABOUL L, O'Donnell CM, Amin M, Rodrigues P, et al
    A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.
    Mult Scler. 2023 Dec 13:13524585231214360. doi: 10.1177/13524585231214360.
    PubMed     Abstract available


  63. DALLA COSTA G, Nos C, Zabalza A, Buron M, et al
    A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
    Mult Scler. 2023 Dec 12:13524585231214362. doi: 10.1177/13524585231214362.
    PubMed     Abstract available


  64. BRUCE JM, Cozart JS, Shook RP, Befort C, et al
    Modifying diet and exercise in multiple sclerosis (MoDEMS): A randomized controlled trial for behavioral weight loss in adults with multiple sclerosis and obesity.
    Mult Scler. 2023;29:1860-1871.
    PubMed     Abstract available


  65. SACCO S, Virupakshaiah A, Papinutto N, Schoeps VA, et al
    Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
    Mult Scler. 2023;29:1736-1747.
    PubMed     Abstract available


  66. LUBLIN FD
    Worsening MS-A reappraisal of how we characterize the MS disease course.
    Mult Scler. 2023;29:1699-1700.
    PubMed    


  67. SAMADZADEH S, Olesen MN, Wirenfeldt M, Moller S, et al
    Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.
    Mult Scler. 2023;29:1721-1735.
    PubMed     Abstract available


  68. PROSCHMANN U, Mueller-Enz M, Woopen C, Katoul Al Rahbani G, et al
    Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
    Mult Scler. 2023;29:1849-1859.
    PubMed     Abstract available


  69. MORROW SA, Weinstock ZL, Mirmosayyeb O, Conway D, et al
    Detecting isolated cognitive relapses in persons with MS.
    Mult Scler. 2023;29:1786-1794.
    PubMed     Abstract available


    November 2023
  70. MATTIESING RM, Kramer E, Strijbis EM, Brouwer I, et al
    Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.
    Mult Scler. 2023 Nov 29:13524585231212879. doi: 10.1177/13524585231212879.
    PubMed     Abstract available


  71. ZHAO T, Taylor BV, Campbell JA, Palmer AJ, et al
    The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
    Mult Scler. 2023 Nov 24:13524585231213230. doi: 10.1177/13524585231213230.
    PubMed     Abstract available


  72. MONTEIRO IR, Moccia M
    Mobile health interventions in multiple sclerosis: Bringing empowerment into clinical practice.
    Mult Scler. 2023 Nov 20:13524585231214879. doi: 10.1177/13524585231214879.
    PubMed    


  73. CASTANO-AMORES C, Nieto-Gomez P
    The crossroads of multiple sclerosis and cancer: Urgent call for clinical direction.
    Mult Scler. 2023 Nov 20:13524585231214171. doi: 10.1177/13524585231214171.
    PubMed    


  74. LADAKIS DC, Reyes-Mantilla MI, Gadani SP, Mace JW, et al
    Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Mult Scler. 2023 Nov 20:13524585231213164. doi: 10.1177/13524585231213164.
    PubMed     Abstract available


  75. NIELSEN NM, Frisch M, Gortz S, Stenager E, et al
    Smoking during pregnancy and risk of multiple sclerosis in offspring and mother: A Danish nationwide register-based cohort study.
    Mult Scler. 2023 Nov 19:13524585231208310. doi: 10.1177/13524585231208310.
    PubMed     Abstract available


  76. BROCHET B, Solari A, Lechner-Scott J, Piehl F, et al
    Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Mult Scler. 2023 Nov 18:13524585231205962. doi: 10.1177/13524585231205962.
    PubMed     Abstract available


  77. NICHOLSON S, Russo AW, Brewer K, Bien H, et al
    The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Mult Scler. 2023 Nov 10:13524585231204710. doi: 10.1177/13524585231204710.
    PubMed     Abstract available


  78. BOU RJEILY N, Fitzgerald KC, Mowry EM
    Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Mult Scler. 2023 Nov 9:13524585231208311. doi: 10.1177/13524585231208311.
    PubMed     Abstract available


  79. AMEZCUA L, Robers MV, Soneji D, Manouvakhova O, et al
    Inclusion of optic neuritis in dissemination in space improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231209016. doi: 10.1177/13524585231209016.
    PubMed     Abstract available


  80. ZICCARDI S, Fuchs T, Dwyer MG, Zivadinov R, et al
    Cognitive phenotypes predict response to restorative cognitive rehabilitation in multiple sclerosis.
    Mult Scler. 2023 Nov 9:13524585231208331. doi: 10.1177/13524585231208331.
    PubMed     Abstract available


  81. VAN KEMPEN ZL, van Dam KP, Keijser JB, Stalman EW, et al
    Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
    Mult Scler. 2023 Nov 9:13524585231207761. doi: 10.1177/13524585231207761.
    PubMed     Abstract available


  82. FEINSTEIN A
    The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.
    Mult Scler. 2023 Nov 2:13524585231210178. doi: 10.1177/13524585231210178.
    PubMed    


  83. CHASE E, Chen V, Martin K, Lane M, et al
    A low-fat diet improves fatigue in multiple sclerosis: Results from a randomized controlled trial.
    Mult Scler. 2023;29:1659-1675.
    PubMed     Abstract available


  84. WEINSTOCK ZL, Jaworski M 3rd, Dwyer MG, Jakimovski D, et al
    Auditory Test of Processing Speed: Preliminary validation of a smartphone-based test of mental speed.
    Mult Scler. 2023;29:1646-1658.
    PubMed     Abstract available


  85. WISHART M, Everest MR, Morrow SA, Rose J, et al
    Establishing the consistency of a voice recognition symbol digit modalities test analogue.
    Mult Scler. 2023;29:1676-1679.
    PubMed     Abstract available


  86. BOCCIA VD, Saitta L, Inglese M, Lapucci C, et al
    Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient.
    Mult Scler. 2023;29:1688-1692.
    PubMed     Abstract available


    October 2023
  87. ONTANEDA D, Amezcua L
    Re-thinking race and geography in multiple sclerosis.
    Mult Scler. 2023 Oct 31:13524585231205969. doi: 10.1177/13524585231205969.
    PubMed    


  88. SINGER BA, Arnold DL, Drulovic J, Freedman MS, et al
    Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2023 Oct 31:13524585231205708. doi: 10.1177/13524585231205708.
    PubMed     Abstract available


  89. HEESEN C, Berger T, Riemann-Lorenz K, Krause N, et al
    Mobile health interventions in multiple sclerosis: A systematic review.
    Mult Scler. 2023 Oct 28:13524585231201089. doi: 10.1177/13524585231201089.
    PubMed     Abstract available


  90. PORWAL MH, Obeidat AZ
    A closer look at reported colitis in association with multiple sclerosis treatments.
    Mult Scler. 2023 Oct 28:13524585231205964. doi: 10.1177/13524585231205964.
    PubMed    


  91. LEARMONTH YC, P Herring M, Russell DI, Pilutti LA, et al
    Safety of exercise training in multiple sclerosis: An updated systematic review and meta-analysis.
    Mult Scler. 2023 Oct 26:13524585231204459. doi: 10.1177/13524585231204459.
    PubMed     Abstract available


  92. RAMARI C, Awadia Z, Bansi J, Casey B, et al
    The MoxFo initiative - outcomes: Outcome measures in studies of exercise training in multiple sclerosis; scoping review of reviews and classification according to the ICF framework.
    Mult Scler. 2023 Oct 26:13524585231204451. doi: 10.1177/13524585231204451.
    PubMed     Abstract available


  93. DALGAS U, Riemenschneider M, Gold SM, Kalron A, et al
    The MoXFo initiative - study design: Considerations related to study design and methodology in exercise research for people with multiple sclerosis.
    Mult Scler. 2023 Oct 26:13524585231204456. doi: 10.1177/13524585231204456.
    PubMed     Abstract available


  94. MANSOUBI M, Learmonth YC, Mayo N, Collet J, et al
    The MoXFo Initiative: Using consensus methodology to move forward towards internationally shared vocabulary in multiple sclerosis exercise research.
    Mult Scler. 2023 Oct 26:13524585231204460. doi: 10.1177/13524585231204460.
    PubMed     Abstract available


  95. ROSENKRANZ SC, Ploughman M, Hvid LG, Zimmer P, et al
    The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies.
    Mult Scler. 2023 Oct 26:13524585231204453. doi: 10.1177/13524585231204453.
    PubMed     Abstract available


  96. MOTL RW, Casey B, Learmonth YC, Latimer-Cheung A, et al
    The MoXFo initiative - adherence: Exercise adherence, compliance and sustainability among people with multiple sclerosis: An overview and roadmap for research.
    Mult Scler. 2023 Oct 26:13524585231204446. doi: 10.1177/13524585231204446.
    PubMed     Abstract available


  97. ZHANG Y, Atkinson J, Burd CE, Graves J, et al
    Biological aging in multiple sclerosis.
    Mult Scler. 2023 Oct 25:13524585231204122. doi: 10.1177/13524585231204122.
    PubMed     Abstract available


  98. BEREK K, Hegen H, Auer M, Barket R, et al
    Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
    Mult Scler. 2023 Oct 18:13524585231201093. doi: 10.1177/13524585231201093.
    PubMed     Abstract available


  99. KOCH MW, Moral E, Brieva L, Mostert J, et al
    Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
    Mult Scler. 2023 Oct 13:13524585231202320. doi: 10.1177/13524585231202320.
    PubMed     Abstract available


  100. DARVISHI S, Donnachie E, Gasperi C, Hapfelmeier A, et al
    Vaccination frequency in people newly diagnosed with multiple sclerosis.
    Mult Scler. 2023 Oct 13:13524585231199084. doi: 10.1177/13524585231199084.
    PubMed     Abstract available


  101. REYES S, Otero-Romero S
    Rethinking vaccination in multiple sclerosis: The way forward.
    Mult Scler. 2023 Oct 3:13524585231204126. doi: 10.1177/13524585231204126.
    PubMed    


  102. LAPUCCI C, Boccia VD, Sirito T, Cellerino M, et al
    Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series.
    Mult Scler. 2023 Oct 3:13524585231204121. doi: 10.1177/13524585231204121.
    PubMed     Abstract available


  103. TIEPPO EMS, Silva GD, Silva TFFD, Araujo RS, et al
    Misdiagnosis in multiple sclerosis in a Brazilian reference center: Clinical, radiological, laboratory profile and failures in the diagnostic process-Cohort study.
    Mult Scler. 2023 Oct 3:13524585231199323. doi: 10.1177/13524585231199323.
    PubMed     Abstract available


  104. JACOBER SLS, Disanto G, Sacco R, Meng D, et al
    Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis.
    Mult Scler. 2023 Oct 3:13524585231199820. doi: 10.1177/13524585231199820.
    PubMed     Abstract available


  105. UHER T, Adzima A, Srpova B, Noskova L, et al
    Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  106. WU Y, Geraldes R, Jurynczyk M, Palace J, et al
    Double-negative neuromyelitis optica spectrum disorder.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  107. THOMPSON AJ, Moccia M, Amato MP, Calabresi PA, et al
    Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.
    Mult Scler. 2023;29.
    PubMed     Abstract available


    September 2023
  108. ANDERSON JR, Fitzgerald KC, Murrough JW, Katz Sand IB, et al
    Depression symptoms and cognition in multiple sclerosis: Longitudinal evidence of a specific link to executive control.
    Mult Scler. 2023 Sep 29:13524585231198746. doi: 10.1177/13524585231198746.
    PubMed     Abstract available


  109. CERDA-FUERTES N, Stoessel M, Mickeliunas G, Pless S, et al
    Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
    Mult Scler. 2023 Sep 29:13524585231198760. doi: 10.1177/13524585231198760.
    PubMed     Abstract available


  110. VERCELLINO M, Costantini G, Cogoni M, Lequio L, et al
    Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study.
    Mult Scler. 2023 Sep 23:13524585231199031. doi: 10.1177/13524585231199031.
    PubMed     Abstract available


  111. FREEDMAN DE, Krysko KM, Feinstein A
    Intimate partner violence and multiple sclerosis.
    Mult Scler. 2023 Sep 21:13524585231197926. doi: 10.1177/13524585231197926.
    PubMed     Abstract available


  112. CARVAJAL R, Tur C, Martinez-Gomez X, Bollo L, et al
    A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients.
    Mult Scler. 2023 Sep 20:13524585231200303. doi: 10.1177/13524585231200303.
    PubMed     Abstract available


  113. MORALES-RODRIGUEZ D, Anderson A, Nylander A, Hsu S, et al
    Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis.
    Mult Scler. 2023 Sep 16:13524585231197056. doi: 10.1177/13524585231197056.
    PubMed     Abstract available


  114. KRAJNC N, Schmidbauer V, Leinkauf J, Haider L, et al
    Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231197954. doi: 10.1177/13524585231197954.
    PubMed     Abstract available


  115. BOSE G, Healy BC, Barro C, Moreira Ferreira VF, et al
    Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis.
    Mult Scler. 2023 Sep 15:13524585231198751. doi: 10.1177/13524585231198751.
    PubMed     Abstract available


  116. MARTIN SJ, Brand-Arzamendi K, Saab G, Muccilli A, et al
    GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231195861. doi: 10.1177/13524585231195861.
    PubMed     Abstract available


  117. MOGHAVEM N, Castaneda GDR, Chatfield AJ, Amezcua L, et al
    The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review.
    Mult Scler. 2023 Sep 12:13524585231197275. doi: 10.1177/13524585231197275.
    PubMed     Abstract available


  118. WANG Y, Bou Rjeily N, Koshorek J, Grkovski R, et al
    Clinical and radiologic characteristics associated with multiple sclerosis misdiagnosis at a tertiary referral center in the United States.
    Mult Scler. 2023 Sep 12:13524585231196795. doi: 10.1177/13524585231196795.
    PubMed     Abstract available


  119. BRUNO A, Buttari F, Dolcetti E, Azzolini F, et al
    Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis.
    Mult Scler. 2023 Sep 12:13524585231197928. doi: 10.1177/13524585231197928.
    PubMed     Abstract available


  120. HAUSER SL, Zielman R, Das Gupta A, Xi J, et al
    Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Mult Scler. 2023 Sep 11:13524585231195346. doi: 10.1177/13524585231195346.
    PubMed     Abstract available


  121. DEJONGE SR, DuBose NG, Pilutti LA, Motl RW, et al
    Arterial stiffness in persons with multiple sclerosis and controls: Does aerobic fitness account for group differences?
    Mult Scler. 2023 Sep 11:13524585231199030. doi: 10.1177/13524585231199030.
    PubMed     Abstract available


    August 2023
  122. HARDY TA
    Pseudocystic demyelination in multiple sclerosis.
    Mult Scler. 2023 Aug 25:13524585231193365. doi: 10.1177/13524585231193365.
    PubMed    


  123. CLUSE F, Fenouil T, Vukusic S, Ducray F, et al
    Pseudocystic inflammatory demyelinating lesions in multiple sclerosis: A clinical, radiological, and pathological description.
    Mult Scler. 2023 Aug 25:13524585231193345. doi: 10.1177/13524585231193345.
    PubMed     Abstract available


  124. BAR-OR A, Cross AH, Cunningham AL, Hyvert Y, et al
    Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
    Mult Scler. 2023 Aug 25:13524585231192460. doi: 10.1177/13524585231192460.
    PubMed     Abstract available


  125. RAIMO S, Santangelo G, Cropano M, Gaita M, et al
    Comparing face-to-face and videoconference assessment of the Brief Repeatable Battery of Neuropsychological Tests in people with multiple sclerosis.
    Mult Scler. 2023 Aug 21:13524585231192469. doi: 10.1177/13524585231192469.
    PubMed     Abstract available


  126. BALSHI A, Saart E, Pandeya S, Dempsey J, et al
    High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
    Mult Scler. 2023 Aug 12:13524585231189641. doi: 10.1177/13524585231189641.
    PubMed     Abstract available


  127. FAN JH, Alexander J, Poole S, Wijangco J, et al
    Characteristics of multiple sclerosis and demyelinating disease in an Asian American population.
    Mult Scler. 2023 Aug 7:13524585231188486. doi: 10.1177/13524585231188486.
    PubMed     Abstract available


  128. MARRIE RA, Bernstein CN, Dolovich C, Bolton JM, et al
    Within-person fluctuations over three years in depression, anxiety, fatigue, and health-related quality of life in multiple sclerosis.
    Mult Scler. 2023 Aug 3:13524585231190771. doi: 10.1177/13524585231190771.
    PubMed     Abstract available


  129. NAKAMURA K, Zheng Y, Mahajan KR, Cohen JA, et al
    Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Mult Scler. 2023 Aug 3:13524585231187289. doi: 10.1177/13524585231187289.
    PubMed     Abstract available


  130. WESSELS MH, Van Lierop ZY, Noteboom S, Strijbis EM, et al
    Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Mult Scler. 2023 Aug 2:13524585231188625. doi: 10.1177/13524585231188625.
    PubMed     Abstract available


  131. TAYLOR LA, Mhizha-Murira JR, Law G, Evangelou N, et al
    Understanding who benefits most from cognitive rehabilitation for multiple sclerosis: A secondary data analysis.
    Mult Scler. 2023 Aug 1:13524585231189470. doi: 10.1177/13524585231189470.
    PubMed     Abstract available


  132. COTE SE, Wagshul ME, Foley FW, Lipton ML, et al
    Caudate volume and symptoms of apathy in older adults with multiple sclerosis.
    Mult Scler. 2023 Aug 1:13524585231188096. doi: 10.1177/13524585231188096.
    PubMed     Abstract available


  133. GRAY E, Amjad A, Robertson J, Beveridge J, et al
    Enhancing involvement of people with multiple sclerosis in clinical trial design.
    Mult Scler. 2023;29:1162-1173.
    PubMed     Abstract available


  134. SORMANI MP, Chataway J, Kent DM, Marrie RA, et al
    Assessing heterogeneity of treatment effect in multiple sclerosis trials.
    Mult Scler. 2023;29:1158-1161.
    PubMed     Abstract available


  135. MARRIE RA, Sormani MP, Apap Mangion S, Bovis F, et al
    Improving the efficiency of clinical trials in multiple sclerosis.
    Mult Scler. 2023;29:1136-1148.
    PubMed     Abstract available


  136. FINLAYSON M, Al-Mashita L, Sandhu R
    Participant diversity in clinical trials of rehabilitation interventions for people with multiple sclerosis: A scoping review.
    Mult Scler. 2023;29:1149-1157.
    PubMed     Abstract available


  137. MARRIE RA, Chataway J, Bierer BE, Finlayson M, et al
    Enhancing diversity of clinical trial populations in multiple sclerosis.
    Mult Scler. 2023;29:1174-1185.
    PubMed     Abstract available


  138. FINLAYSON M, Feys P, Dalgas U, Kos D, et al
    Intermediate outcomes for clinical trials of multiple sclerosis rehabilitation interventions: Conceptual and practical considerations.
    Mult Scler. 2023;29:1186-1194.
    PubMed     Abstract available


  139. GIOVANNONI G
    Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
    Mult Scler. 2023;29:1068-1069.
    PubMed    


  140. STRIJBIS E, Koch MW, de Jong BA
    Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.
    Mult Scler. 2023;29:1066-1067.
    PubMed    


  141. GOVEROVER Y, Chiaravalloti N
    Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
    Mult Scler. 2023;29:1064-1065.
    PubMed    


  142. COHEN M, Thomel-Rocchi O, Siva A, Okuda DT, et al
    Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
    Mult Scler. 2023;29:1099-1106.
    PubMed     Abstract available


    July 2023
  143. CAVALLA P, Vercellino M
    May Mediterranean diet contribute to reduce risk of multiple sclerosis?
    Mult Scler. 2023 Jul 29:13524585231190342. doi: 10.1177/13524585231190342.
    PubMed    


  144. GUNZLER DD, De Nadai AS, Miller DM, Ontaneda D, et al
    Long-term trajectories of ambulatory impairment in multiple sclerosis.
    Mult Scler. 2023 Jul 28:13524585231187521. doi: 10.1177/13524585231187521.
    PubMed     Abstract available


  145. JAWORSKI MG 3RD, Gillies JK, Youngs M, Wojcik C, et al
    Predicting employment deterioration with the Processing Speed Test (PST) and SDMT in multiple sclerosis.
    Mult Scler. 2023 Jul 28:13524585231187283. doi: 10.1177/13524585231187283.
    PubMed     Abstract available


  146. GOVEROVER Y, Amber S, John D
    Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality(TM).
    Mult Scler. 2023 Jul 26:13524585231185048. doi: 10.1177/13524585231185048.
    PubMed     Abstract available


  147. DE GIER M, Beckerman H, Twisk J, Knoop H, et al
    Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT.
    Mult Scler. 2023 Jul 25:13524585231185462. doi: 10.1177/13524585231185462.
    PubMed     Abstract available


  148. TITBALL RW, Lewis N, Nicholas R
    Is Clostridium perfringens epsilon toxin associated with multiple sclerosis?
    Mult Scler. 2023 Jul 22:13524585231186899. doi: 10.1177/13524585231186899.
    PubMed     Abstract available


  149. COHEN JA
    Commentary: Solomon AJ et al. Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. Lancet Neurol (in press).
    Mult Scler. 2023 Jul 20:13524585231188097. doi: 10.1177/13524585231188097.
    PubMed    


  150. BOLES GS, Hillert J, Ramanujam R, Westerlind H, et al
    The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case-control study.
    Mult Scler. 2023 Jul 12:13524585231185258. doi: 10.1177/13524585231185258.
    PubMed     Abstract available


  151. ORLANDO CM, Perez CA, Agyei P, Elsehety M, et al
    Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis.
    Mult Scler. 2023 Jul 12:13524585231185046. doi: 10.1177/13524585231185046.
    PubMed     Abstract available


  152. SIPILA JO, Viitala M, Hanninen A, Soilu-Hanninen M, et al
    Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis.
    Mult Scler. 2023 Jul 10:13524585231185045. doi: 10.1177/13524585231185045.
    PubMed     Abstract available


  153. NEYAL N, Keegan BM, Kantarci OH, Zeydan B, et al
    Coexistence of multiple sclerosis and spinocerebellar ataxia type-8.
    Mult Scler. 2023 Jul 3:13524585231180549. doi: 10.1177/13524585231180549.
    PubMed     Abstract available


  154. KLINEOVA S, Farber RS, DeAngelis T, Leung T, et al
    Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
    Mult Scler. 2023;29:990-1000.
    PubMed     Abstract available


  155. ZALOUM SA, Wood CH, Tank P, Upcott M, et al
    Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination.
    Mult Scler. 2023;29:979-989.
    PubMed     Abstract available


  156. REEVES JA, Weinstock Z, Zivadinov R, Dwyer MG, et al
    Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse.
    Mult Scler. 2023;29:1033-1038.
    PubMed     Abstract available


  157. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
    A taxonomic approach to cognitive diagnostics is viable and achievable in MS.
    Mult Scler. 2023;29:1040-1042.
    PubMed    


    June 2023
  158. HE AH, Manouchehrinia A, Glaser A, Ciccarelli O, et al
    Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.
    Mult Scler. 2023 Jun 30:13524585231181578. doi: 10.1177/13524585231181578.
    PubMed     Abstract available


  159. ALFREDSSON L, Olsson T, Hedstrom AK
    Inverse association between Mediterranean diet and risk of multiple sclerosis.
    Mult Scler. 2023 Jun 27:13524585231181841. doi: 10.1177/13524585231181841.
    PubMed     Abstract available


  160. JIANG X, Shen C, Teunissen CE, Wessels M, et al
    Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
    Mult Scler. 2023 Jun 15:13524585231176732. doi: 10.1177/13524585231176732.
    PubMed     Abstract available


  161. SMOOT K, Marginean H, Gervasi-Follmar T, Chen C, et al
    Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
    Mult Scler. 2023 Jun 15:13524585231175284. doi: 10.1177/13524585231175284.
    PubMed     Abstract available


  162. OTERO-ROMERO S, Lebrun-Frenay C, Reyes S, Amato MP, et al
    ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
    Mult Scler. 2023 Jun 9:13524585231168043. doi: 10.1177/13524585231168043.
    PubMed     Abstract available


  163. NYLANDER AN, Singh J, Poole S, Anderson A, et al
    Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.
    Mult Scler. 2023 Jun 8:13524585231175975. doi: 10.1177/13524585231175975.
    PubMed     Abstract available


  164. DELAVAL S, Dequirez PL, Hentzen C, Baron M, et al
    Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee o
    Mult Scler. 2023 Jun 2:13524585231174580. doi: 10.1177/13524585231174580.
    PubMed     Abstract available


  165. LUBLIN FD, Krieger SC
    MS becomes a treatable disease: 30 years later.
    Mult Scler. 2023;29:789-792.
    PubMed     Abstract available


  166. REDENBAUGH V, Chia NH, Cacciaguerra L, McCombe JA, et al
    Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Mult Scler. 2023;29:799-808.
    PubMed     Abstract available


  167. LEBRUN-FRENAY C, Okuda DT
    Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
    Mult Scler. 2023;29:793-795.
    PubMed    


  168. INGLESE M, Amato MP
    Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary.
    Mult Scler. 2023;29:797-798.
    PubMed    


  169. SMETS I
    Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated - NO.
    Mult Scler. 2023;29:795-797.
    PubMed    


  170. HUMMERT MW, Stern C, Paul F, Duchow A, et al
    Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
    Mult Scler. 2023;29:819-831.
    PubMed     Abstract available


    May 2023
  171. BANWELL B
    Pediatric multiple sclerosis: The 2022 ECTRIMS lecture.
    Mult Scler. 2023 May 30:13524585231171047. doi: 10.1177/13524585231171047.
    PubMed     Abstract available


  172. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Sars-CoV2 infection in pregnant women with multiple sclerosis.
    Mult Scler. 2023 May 26:13524585231176174. doi: 10.1177/13524585231176174.
    PubMed     Abstract available


  173. ALSHEHRI E, Cohen JA, Ontaneda D, Nakamura K, et al
    The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis.
    Mult Scler. 2023 May 19:13524585231172490. doi: 10.1177/13524585231172490.
    PubMed     Abstract available


  174. VIRUPAKSHAIAH A, Ladakis DC, Nourbakhsh B, Bhargava P, et al
    Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis.
    Mult Scler. 2023 May 18:13524585231171517. doi: 10.1177/13524585231171517.
    PubMed     Abstract available


  175. VALENTINE TR, Kratz AL, Kaplish N, Chervin RD, et al
    Sleep-disordered breathing and neurocognitive function in multiple sclerosis: Differential associations across cognitive domains.
    Mult Scler. 2023 May 17:13524585231169465. doi: 10.1177/13524585231169465.
    PubMed     Abstract available


  176. CAPUANO R, Prosperini L, Altieri M, Lorefice L, et al
    Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
    Mult Scler. 2023 May 11:13524585231167515. doi: 10.1177/13524585231167515.
    PubMed     Abstract available


  177. SAUL AM, Taylor BV, Blizzard L, Simpson-Yap S, et al
    A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study.
    Mult Scler. 2023 May 6:13524585231167739. doi: 10.1177/13524585231167739.
    PubMed     Abstract available


  178. KOLIND S, Gaetano L, Assemlal HE, Bernasconi C, et al
    Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
    Mult Scler. 2023;29:741-747.
    PubMed     Abstract available


    April 2023
  179. MARRIE RA
    The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward.
    Mult Scler. 2023 Apr 26:13524585231167740. doi: 10.1177/13524585231167740.
    PubMed     Abstract available


  180. FINK K, Gorczyca A, Alping P, Englund S, et al
    Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study.
    Mult Scler. 2023 Apr 18:13524585231161492. doi: 10.1177/13524585231161492.
    PubMed     Abstract available


  181. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Michaux K, et al
    Employment status, productivity loss, and associated factors among people with multiple sclerosis.
    Mult Scler. 2023 Apr 15:13524585231164295. doi: 10.1177/13524585231164295.
    PubMed     Abstract available


  182. ELLIOTT C, Rudko DA, Arnold DL, Fetco D, et al
    Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
    Mult Scler. 2023 Apr 10:13524585231162262. doi: 10.1177/13524585231162262.
    PubMed     Abstract available


  183. PALLADINO R, Marrie RA, Majeed A, Chataway J, et al
    Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.
    Mult Scler. 2023 Apr 7:13524585231164296. doi: 10.1177/13524585231164296.
    PubMed     Abstract available


  184. GIOVANNONI G, Boyko A, Correale J, Edan G, et al
    Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Mult Scler. 2023 Apr 3:13524585231161494. doi: 10.1177/13524585231161494.
    PubMed     Abstract available


  185. SATYANARAYAN S, Cutter G, Krieger S, Cofield S, et al
    The impact of relapse definition and measures of durability on MS clinical trial outcomes.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  186. WITTAYER M, Weber CE, Kittel M, Platten M, et al
    Cerebrospinal fluid-related tissue damage in multiple sclerosis patients with iron rim lesions.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  187. KLISTORNER S, Van der Walt A, Barnett MH, Butzkueven H, et al
    Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  188. ROTSTEIN DL, Wolfson C, Carruthers R, Freedman MS, et al
    A national case-control study investigating demographic and environmental factors associated with NMOSD.
    Mult Scler. 2023;29.
    PubMed     Abstract available


  189. TOHYAMA S, Oh J, Timm M, Cheng JC, et al
    Should trigeminal neuralgia be considered a clinically isolated syndrome?
    Mult Scler. 2023;29.
    PubMed     Abstract available


  190. ROMAN S
    A journey with no roadmap-The need for validated criteria of the MS prodrome.
    Mult Scler. 2023;29.
    PubMed     Abstract available


    March 2023
  191. OTTO C, Schwarz T, Jeworowski LM, Schmidt ML, et al
    Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20-treated patients with multiple sclerosis after three or four COVID-19 vaccinations.
    Mult Scler. 2023 Mar 28:13524585231161253. doi: 10.1177/13524585231161253.
    PubMed     Abstract available


  192. SIMON S, Nauta IM, Hillebrand A, Schoonheim MM, et al
    Neurophysiological MEG markers of cognitive impairment and performance validity in multiple sclerosis.
    Mult Scler. 2023 Mar 25:13524585231159817. doi: 10.1177/13524585231159817.
    PubMed     Abstract available


  193. GHEZZI A, Neuteboom RF
    The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized T
    Mult Scler. 2023 Mar 23:13524585231161148. doi: 10.1177/13524585231161148.
    PubMed    


  194. SCHREINER T, Wilson-Murphy M, Mendelt-Tillema J, Waltz M, et al
    Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
    Mult Scler. 2023 Mar 23:13524585231151948. doi: 10.1177/13524585231151948.
    PubMed     Abstract available


  195. MARRODAN M, Piedrabuena MA, Gaitan MI, Fiol MP, et al
    Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina.
    Mult Scler. 2023 Mar 21:13524585231157276. doi: 10.1177/13524585231157276.
    PubMed     Abstract available


  196. MOTL RW, Kidwell-Chandler A, Sandroff BM, Pilutti LA, et al
    Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.
    Mult Scler. 2023;29:415-426.
    PubMed     Abstract available


  197. KUHLE J, Chitnis T, Banwell B, Tardieu M, et al
    Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Mult Scler. 2023;29:385-394.
    PubMed     Abstract available


  198. TOOROP AA, Steenhuis M, Loeff FC, Weijers SS, et al
    Fingerprick blood samples to measure serum natalizumab concentrations.
    Mult Scler. 2023;29:457-460.
    PubMed     Abstract available


    February 2023
  199. DARUWALLA C, Shaygannejad V, Ozakbas S, Havrdova EK, et al
    Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
    Mult Scler. 2023 Feb 27:13524585231151951. doi: 10.1177/13524585231151951.
    PubMed     Abstract available


  200. SANDRY J, Levy S, Sumowski JF
    Psychometrically valid interpretation of cognitive assessments is a prerequisite for classification of cognitive phenotypes in multiple sclerosis.
    Mult Scler. 2023 Feb 21:13524585231157000. doi: 10.1177/13524585231157000.
    PubMed    


  201. DOLCETTI E, Bruno A, Azzolini F, Gilio L, et al
    Genetic regulation of IL-8 influences disease presentation of multiple sclerosis.
    Mult Scler. 2023 Feb 19:13524585231155049. doi: 10.1177/13524585231155049.
    PubMed     Abstract available


  202. DANG YL, Yong VT, Sharmin S, Perucca P, et al
    Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis.
    Mult Scler. 2023 Feb 19:13524585231151400. doi: 10.1177/13524585231151400.
    PubMed     Abstract available


  203. ROOS I, Diouf I, Sharmin S, Horakova D, et al
    Comparative effectiveness in multiple sclerosis: A methodological comparison.
    Mult Scler. 2023 Feb 19:13524585231151394. doi: 10.1177/13524585231151394.
    PubMed     Abstract available


  204. MANOUCHEHRINIA A, Larsson H, Karim ME, Lycke J, et al
    Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
    Mult Scler. 2023 Feb 15:13524585231153992. doi: 10.1177/13524585231153992.
    PubMed     Abstract available


  205. HORTON MK, Shim JE, Wallace A, Graves JS, et al
    Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis.
    Mult Scler. 2023 Feb 8:13524585221150736. doi: 10.1177/13524585221150736.
    PubMed     Abstract available


  206. LAM KH, Bucur IG, van Oirschot P, de Graaf F, et al
    Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis.
    Mult Scler. 2023 Feb 8:13524585231152433. doi: 10.1177/13524585231152433.
    PubMed     Abstract available


  207. IYER P, Wiles K, Ismail A, Nanda S, et al
    Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus.
    Mult Scler. 2023 Feb 5:13524585221148094. doi: 10.1177/13524585221148094.
    PubMed     Abstract available


  208. STEFANOU MI, Palaiodimou L, Theodorou A, Christodoulou MV, et al
    Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2023 Feb 1:13524585221150881. doi: 10.1177/13524585221150881.
    PubMed     Abstract available


  209. CARNERO CONTENTTI E, Lopez PA, Criniti J, Alonso R, et al
    Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors.
    Mult Scler. 2023;29:277-286.
    PubMed     Abstract available


  210. BRENTON JN, Piccio L
    Strengthening the link: Diet quality and disability in MS.
    Mult Scler. 2023;29:157-159.
    PubMed    


    January 2023
  211. CHIA NH, Redenbaugh V, Chen JJ, Pittock SJ, et al
    Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis.
    Mult Scler. 2023 Jan 24:13524585221150743. doi: 10.1177/13524585221150743.
    PubMed     Abstract available


  212. HU C, Dewey BE, Mowry EM, Fitzgerald KC, et al
    Deep gray matter substructure volumes and depressive symptoms in a large multiple sclerosis cohort.
    Mult Scler. 2023 Jan 24:13524585221148144. doi: 10.1177/13524585221148144.
    PubMed     Abstract available


  213. SADOVNICK D, Criscuoli M, Yee I, Carruthers R, et al
    The Canadian Multiple Sclerosis Pregnancy Study: First-trimester miscarriages in women with multiple sclerosis.
    Mult Scler. 2023 Jan 22:13524585221146270. doi: 10.1177/13524585221146270.
    PubMed     Abstract available


  214. ABBADESSA G, Miele G, Maida E, Vanore E, et al
    Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis.
    Mult Scler. 2023 Jan 22:13524585221147635. doi: 10.1177/13524585221147635.
    PubMed     Abstract available


  215. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life.
    Mult Scler. 2023 Jan 19:13524585221144413. doi: 10.1177/13524585221144413.
    PubMed     Abstract available


  216. ANDERSON J, Sumowski JF
    Towards a phenotypic understanding of multiple sclerosis depression.
    Mult Scler. 2023 Jan 12:13524585221148143. doi: 10.1177/13524585221148143.
    PubMed    


  217. BRALEY TJ, Shieu MM, Zaheed AB, Dunietz GL, et al
    Pathways between multiple sclerosis, sleep disorders, and cognitive function: Longitudinal findings from The Nurses' Health Study.
    Mult Scler. 2023 Jan 12:13524585221144215. doi: 10.1177/13524585221144215.
    PubMed     Abstract available


  218. GRECH LB
    Addressing me in the context of my disease: Why it is so complicated.
    Mult Scler. 2023;29:8-10.
    PubMed     Abstract available


  219. KRUPP LB, Waubant E, Waltz M, Casper TC, et al
    A new look at cognitive functioning in pediatric MS.
    Mult Scler. 2023;29:140-149.
    PubMed     Abstract available


  220. FRIEDLI C, Wagner F, Hammer HN, Kamber N, et al
    Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
    Mult Scler. 2023;29:63-73.
    PubMed     Abstract available


  221. JACKSON-TARLTON CS, Flanagan EP, Messina SA, Barakat B, et al
    Progressive motor impairment from "critical" demyelinating lesions of the cervicomedullary junction.
    Mult Scler. 2023;29:74-80.
    PubMed     Abstract available


    December 2022
  222. BLOCK VJ, Cheng S, Juwono J, Cuneo R, et al
    Association of daily physical activity with brain volumes and cervical spinal cord areas in multiple sclerosis.
    Mult Scler. 2022 Dec 27:13524585221143726. doi: 10.1177/13524585221143726.
    PubMed     Abstract available


  223. FOX RJ, Tervonen T, Phillips-Beyer A, Sidorenko T, et al
    The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
    Mult Scler. 2022 Dec 22:13524585221140270. doi: 10.1177/13524585221140270.
    PubMed     Abstract available


  224. TSAGKAS C, Huck-Horvath A, Cagol A, Haas T, et al
    Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221139152. doi: 10.1177/13524585221139152.
    PubMed     Abstract available


  225. JAKIMOVSKI D, Kavak KS, Zakalik K, Coetzee T, et al
    Improvement in time to multiple sclerosis diagnosis: 25-year retrospective analysis from New York State MS Consortium (NYSMSC).
    Mult Scler. 2022 Dec 22:13524585221140271. doi: 10.1177/13524585221140271.
    PubMed     Abstract available


  226. LONGONI G, Martinez Chavez E, Young K, Brown RA, et al
    Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis.
    Mult Scler. 2022 Dec 22:13524585221137500. doi: 10.1177/13524585221137500.
    PubMed     Abstract available


  227. KRAJNC N, Dal-Bianco A, Leutmezer F, Kasprian G, et al
    Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis.
    Mult Scler. 2022 Dec 20:13524585221138486. doi: 10.1177/13524585221138486.
    PubMed     Abstract available


  228. HEGEN H, Arrambide G, Gnanapavan S, Kaplan B, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.
    Mult Scler. 2022 Dec 17:13524585221134217. doi: 10.1177/13524585221134217.
    PubMed     Abstract available


  229. CALVI A, Clarke MA, Prados F, Chard D, et al
    Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141964. doi: 10.1177/13524585221141964.
    PubMed     Abstract available


  230. SABATHE C, Casey R, Vukusic S, Leray E, et al
    Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
    Mult Scler. 2022 Dec 14:13524585221139156. doi: 10.1177/13524585221139156.
    PubMed     Abstract available


  231. DE MEO E, Portaccio E
    It is time to define cognitive phenotypes in multiple sclerosis.
    Mult Scler. 2022 Dec 14:13524585221141263. doi: 10.1177/13524585221141263.
    PubMed    


  232. JOKUBAITIS VG
    A role for HLA in mediating long-term multiple sclerosis outcomes?
    Mult Scler. 2022 Dec 14:13524585221139767. doi: 10.1177/13524585221139767.
    PubMed    


  233. BOCCIA VD, Lapucci C, Cellerino M, Tazza F, et al
    Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study.
    Mult Scler. 2022 Dec 13:13524585221142319. doi: 10.1177/13524585221142319.
    PubMed     Abstract available


  234. ABDEL-MANNAN O, Ciccarelli O
    Is the central vein sign a useful diagnostic marker for paediatric-onset multiple sclerosis?
    Mult Scler. 2022 Dec 13:13524585221142318. doi: 10.1177/13524585221142318.
    PubMed    


  235. OKUDA DT, Stanley T, McCreary M, Smith A, et al
    Selective vulnerability of brainstem and cervical spinal cord regions in people with non-progressive multiple sclerosis of Black or African American and European ancestry.
    Mult Scler. 2022 Dec 12:13524585221139575. doi: 10.1177/13524585221139575.
    PubMed     Abstract available


  236. HEGEN H, Walde J, Berek K, Arrambide G, et al
    Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis.
    Mult Scler. 2022 Dec 1:13524585221134213. doi: 10.1177/13524585221134213.
    PubMed     Abstract available


    November 2022
  237. MOTTE J, Gold R
    Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137275. doi: 10.1177/13524585221137275.
    PubMed    


  238. BARRITT AW, Das E, Morley N, Seymour M, et al
    Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221137279. doi: 10.1177/13524585221137279.
    PubMed     Abstract available


  239. MORADI N, Sharmin S, Malpas CB, Shaygannejad V, et al
    External validation of a clinical prediction model in multiple sclerosis.
    Mult Scler. 2022 Nov 30:13524585221136036. doi: 10.1177/13524585221136036.
    PubMed     Abstract available



  240. Corrigendum for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Nov 30:13524585221138507. doi: 10.1177/13524585221138507.
    PubMed    


  241. BARRO C, Healy BC, Saxena S, Glanz BI, et al
    Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients.
    Mult Scler. 2022 Nov 30:13524585221137697. doi: 10.1177/13524585221137697.
    PubMed     Abstract available


  242. REDER AT, Stuve O, Tankou SK, Leist TP, et al
    T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
    Mult Scler. 2022 Nov 28:13524585221134216. doi: 10.1177/13524585221134216.
    PubMed     Abstract available


  243. SPELMAN T, Ozakbas S, Alroughani R, Terzi M, et al
    Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Mult Scler. 2022 Nov 26:13524585221137502. doi: 10.1177/13524585221137502.
    PubMed     Abstract available


  244. BROWNLEE WJ, Tur C, Manole A, Eshaghi A, et al
    HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis.
    Mult Scler. 2022 Nov 18:13524585221130941. doi: 10.1177/13524585221130941.
    PubMed     Abstract available


  245. FOLEY J, Xiong K, Hoyt T, Singh CM, et al
    Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice.
    Mult Scler. 2022 Nov 15:13524585221130949. doi: 10.1177/13524585221130949.
    PubMed     Abstract available


  246. VUKUSIC S, Marignier R, Ciron J, Bourre B, et al
    Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
    Mult Scler. 2022 Nov 8:13524585221130934. doi: 10.1177/13524585221130934.
    PubMed     Abstract available


  247. BROWNLEE WJ
    Cladribine-induced liver injury: Implications for practice.
    Mult Scler. 2022;28:2146.
    PubMed    


  248. CAMARA-LEMARROY C, Metz L, Kuhle J, Leppert D, et al
    Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Mult Scler. 2022;28:2081-2089.
    PubMed     Abstract available


  249. VUKUSIC S, Carra-Dalliere C, Ciron J, Maillart E, et al
    Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
    Mult Scler. 2022 Nov 1:13524585221129472. doi: 10.1177/13524585221129472.
    PubMed     Abstract available


    October 2022
  250. CHERTCOFF A, Ng HS, Zhu F, Zhao Y, et al
    Polypharmacy and multiple sclerosis: A population-based study.
    Mult Scler. 2022 Oct 27:13524585221122207. doi: 10.1177/13524585221122207.
    PubMed     Abstract available


  251. CALOCER F, Ng HS, Zhu F, Zhao Y, et al
    Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis.
    Mult Scler. 2022 Oct 25:13524585221129963. doi: 10.1177/13524585221129963.
    PubMed     Abstract available


  252. DOST-KOVALSKY K, Thiel S, Ciplea AI, Gold R, et al
    Cladribine and pregnancy in women with multiple sclerosis: The first cohort study.
    Mult Scler. 2022 Oct 22:13524585221131486. doi: 10.1177/13524585221131486.
    PubMed     Abstract available


  253. CARDENAS-ROBLEDO S, Gonzalez-Caicedo P, Carvajal-Parra MS, Guio-Sanchez CM, et al
    No seasonality in the risk of multiple sclerosis in an equatorial country: A case-control ecological study.
    Mult Scler. 2022 Oct 15:13524585221130020. doi: 10.1177/13524585221130020.
    PubMed     Abstract available


  254. BOURDETTE D, Herink M
    Polypharmacy in multiple sclerosis: More is not necessarily better.
    Mult Scler. 2022 Oct 14:13524585221129964. doi: 10.1177/13524585221129964.
    PubMed    


  255. HANCOCK LM, Galioto R, Samsonov A, Busch RM, et al
    A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS).
    Mult Scler. 2022 Oct 14:13524585221127941. doi: 10.1177/13524585221127941.
    PubMed     Abstract available


  256. KATZ SAND I, Levy S, Fitzgerald K, Sorets T, et al
    Mediterranean diet is linked to less objective disability in multiple sclerosis.
    Mult Scler. 2022 Oct 13:13524585221127414. doi: 10.1177/13524585221127414.
    PubMed     Abstract available


  257. HUISKAMP M, Kiljan S, Kulik S, Witte ME, et al
    Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study.
    Mult Scler. 2022 Oct 3:13524585221125381. doi: 10.1177/13524585221125381.
    PubMed     Abstract available


  258. PAUWELS A, Van Schependom J, Devolder L, Van Remoortel A, et al
    Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Mult Scler. 2022;28:1685-1696.
    PubMed     Abstract available


  259. FORD CC, Cohen JA, Goodman AD, Lindsey JW, et al
    Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
    Mult Scler. 2022;28:1729-1743.
    PubMed     Abstract available


  260. HARDY TA, Guo Y, Flanagan EP, Lucchinetti CF, et al
    The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
    Mult Scler. 2022;28:1710-1718.
    PubMed     Abstract available


  261. CAPANNA M, Signori A, Sormani MP
    Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials.
    Mult Scler. 2022;28:1744-1751.
    PubMed     Abstract available


  262. ZARGHAMI A, van der Mei I, Hussain MA, Claflin SB, et al
    Long-term trajectories of employment status, workhours and disability support pension status, after a first episode of CNS demyelination.
    Mult Scler. 2022;28:1793-1807.
    PubMed     Abstract available


  263. GRAF J, Ng HS, Zhu F, Zhao Y, et al
    Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
    Mult Scler. 2022;28:1825-1828.
    PubMed     Abstract available


  264. GAETANI L, Schoonheim MM
    Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures.
    Mult Scler. 2022;28:1831-1833.
    PubMed    


  265. KOUBIYR I, Broeders TA, Deloire M, Brochet B, et al
    Altered functional brain states predict cognitive decline 5 years after a clinically isolated syndrome.
    Mult Scler. 2022;28:1973-1982.
    PubMed     Abstract available


  266. ARNOLD DL, Sprenger T, Bar-Or A, Wolinsky JS, et al
    Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Mult Scler. 2022;28:1927-1936.
    PubMed     Abstract available


  267. BESSING B, Claflin SB, Taylor BV, Blizzard L, et al
    Estimating the impact of work difficulties, work self-efficacy and work psychological safety on MS-related work productivity loss.
    Mult Scler. 2022;28:1983-1996.
    PubMed     Abstract available



  268. ECTRIMS 2022 Committees.
    Mult Scler. 2022;28.
    PubMed    


    September 2022
  269. BUHLER A, Wolbers M, Model F, Wang Q, et al
    Recurrent disability progression endpoints in multiple sclerosis clinical trials.
    Mult Scler. 2022 Sep 30:13524585221125382. doi: 10.1177/13524585221125382.
    PubMed     Abstract available


  270. ALEXANDER S, Braisher M, Tur C, Chataway J, et al
    The mSteps pilot study: Analysis of the distance walked using a novel smartphone application in multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221124043. doi: 10.1177/13524585221124043.
    PubMed     Abstract available


  271. STRIK M, Eijlers AJ, Dekker I, Broeders TA, et al
    Sensorimotor network dynamics predict decline in upper and lower limb function in people with multiple sclerosis.
    Mult Scler. 2022 Sep 30:13524585221125372. doi: 10.1177/13524585221125372.
    PubMed     Abstract available


  272. SARACENO L, Pirro F, Stigliano R, Agostoni EC, et al
    Acute idiosyncratic liver injury after Cladribine treatment for multiple sclerosis: first case report and review on associated hepatic disorders.
    Mult Scler. 2022 Sep 28:13524585221125360. doi: 10.1177/13524585221125360.
    PubMed     Abstract available


  273. BRUIJSTENS AL, Stingl C, Guzel C, Stoop MP, et al
    Neurodegeneration and humoral response proteins in cerebrospinal fluid associate with pediatric-onset multiple sclerosis and not monophasic demyelinating syndromes in childhood.
    Mult Scler. 2022 Sep 24:13524585221125369. doi: 10.1177/13524585221125369.
    PubMed     Abstract available


  274. POL-PATIL J, Glanz B, Safar L, Misasi E, et al
    MeTooMS: Sexual, physical, and emotional abuse experience among women with multiple sclerosis.
    Mult Scler. 2022 Sep 24:13524585221122169. doi: 10.1177/13524585221122169.
    PubMed     Abstract available


  275. CHANG I, Kappos L, Giovannoni G, Calabresi PA, et al
    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
    Mult Scler. 2022 Sep 21:13524585221114997. doi: 10.1177/13524585221114997.
    PubMed     Abstract available


  276. COHEN JA, Lublin FD, Lock C, Pelletier D, et al
    Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis.
    Mult Scler. 2022 Sep 14:13524585221122156. doi: 10.1177/13524585221122156.
    PubMed     Abstract available


  277. VAN LIEROP ZY, Noteboom S, Steenwijk MD, van Dam M, et al
    Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.
    Mult Scler. 2022 Sep 3:13524585221118676. doi: 10.1177/13524585221118676.
    PubMed     Abstract available


  278. MCGINLEY MP, Lapin B
    The value of patient-reported outcome measures for multiple sclerosis.
    Mult Scler. 2022;28:1489-1490.
    PubMed    


  279. STRIJBIS EM, Repovic P, Mostert J, Bowen JD, et al
    The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
    Mult Scler. 2022;28:1606-1619.
    PubMed     Abstract available


  280. KLISTORNER S, Barnett MH, Graham SL, Wang C, et al
    The expansion and severity of chronic MS lesions follows a periventricular gradient.
    Mult Scler. 2022;28:1504-1514.
    PubMed     Abstract available


  281. XIANG B, Brier MR, Kanthamneni M, Wen J, et al
    Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Mult Scler. 2022;28:1515-1525.
    PubMed     Abstract available


  282. THEBAULT S, Bose G, Booth R, Freedman MS, et al
    Serum neurofilament light in MS: The first true blood-based biomarker?
    Mult Scler. 2022;28:1491-1497.
    PubMed     Abstract available


  283. PORTACCIO E, Amato MP
    Reliable change indices for cognitive assessment of patients with multiple sclerosis.
    Mult Scler. 2022 Sep 1:13524585221116273. doi: 10.1177/13524585221116273.
    PubMed    


    August 2022
  284. MEATON I, Altokhis A, Allen CM, Clarke MA, et al
    Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
    Mult Scler. 2022 Aug 26:13524585221118677. doi: 10.1177/13524585221118677.
    PubMed     Abstract available


  285. BROWNLEE WJ, Wolf C, Hartung HP, Dingermann T, et al
    Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.
    Mult Scler. 2022 Aug 24:13524585221116269. doi: 10.1177/13524585221116269.
    PubMed     Abstract available


  286. ALTOKHIS AI, Hibbert AM, Allen CM, Mougin O, et al
    Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis.
    Mult Scler. 2022 Aug 24:13524585221114750. doi: 10.1177/13524585221114750.
    PubMed     Abstract available


  287. YOUNG CA, Mills RJ, Langdon D, Rog DJ, et al
    Measuring coping in multiple sclerosis: The Coping Index-MS.
    Mult Scler. 2022 Aug 24:13524585221114004. doi: 10.1177/13524585221114004.
    PubMed     Abstract available


  288. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
    Mult Scler. 2022 Aug 15:13524585221114007. doi: 10.1177/13524585221114007.
    PubMed     Abstract available


  289. BLYAU S, Koubiyr I, Saranathan M, Coupe P, et al
    Differential vulnerability of thalamic nuclei in multiple sclerosis.
    Mult Scler. 2022 Aug 12:13524585221114247. doi: 10.1177/13524585221114247.
    PubMed     Abstract available


  290. CONWAY SE, Pua DKA, Holroyd KB, Galetta K, et al
    Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors.
    Mult Scler. 2022 Aug 11:13524585221117949. doi: 10.1177/13524585221117949.
    PubMed     Abstract available


  291. WILLIAMS T, Tur C, Eshaghi A, Doshi A, et al
    Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial.
    Mult Scler. 2022 Aug 9:13524585221114441. doi: 10.1177/13524585221114441.
    PubMed     Abstract available


  292. CIFTCI KAVAKLIOGLU B, Erdman L, Goldenberg A, Kavaklioglu C, et al
    Machine learning classification of multiple sclerosis in children using optical coherence tomography.
    Mult Scler. 2022 Aug 9:13524585221112605. doi: 10.1177/13524585221112605.
    PubMed     Abstract available


  293. UCCELLI A, Freedman MS
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No.
    Mult Scler. 2022;28:1326-1328.
    PubMed    


  294. PERUZZOTTI-JAMETTI L, Pluchino S
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis ready for prime time: Commentary.
    Mult Scler. 2022;28:1328-1329.
    PubMed    


  295. KARUSSIS D, Kassis I, Petrou P
    Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.
    Mult Scler. 2022;28:1324-1326.
    PubMed    


  296. SESEL AL, Sharpe L, Beadnall HN, Barnett MH, et al
    A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression.
    Mult Scler. 2022;28:1392-1401.
    PubMed     Abstract available


    July 2022
  297. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    PubMed     Abstract available


  298. ZHONG M, van der Walt A, Monif M, Hodgkinson S, et al
    Prediction of relapse activity when switching to cladribine for multiple sclerosis.
    Mult Scler. 2022 Jul 27:13524585221111677. doi: 10.1177/13524585221111677.
    PubMed     Abstract available


  299. KLISTORNER S, Barnett MH, Klistorner A
    Mechanisms of central brain atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 21:13524585221111684. doi: 10.1177/13524585221111684.
    PubMed     Abstract available


  300. JOHNSSON M, Farman HH, Blennow K, Zetterberg H, et al
    No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Mult Scler. 2022 Jul 20:13524585221108080. doi: 10.1177/13524585221108080.
    PubMed     Abstract available


  301. MAGYARI M, Joensen H, Kopp TI, Pontieri L, et al
    Changes in prognosis of the Danish multiple sclerosis population over time.
    Mult Scler. 2022 Jul 13:13524585221110582. doi: 10.1177/13524585221110582.
    PubMed     Abstract available


  302. KRIEGER SC, Antoine A, Sumowski JF
    EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold.
    Mult Scler. 2022 Jul 13:13524585221108297. doi: 10.1177/13524585221108297.
    PubMed     Abstract available


  303. ANNA KARIN H, Erik S, Tim S, Lars F, et al
    The impact of bariatric surgery on disease activity and progression of multiple sclerosis: A nationwide matched cohort study.
    Mult Scler. 2022 Jul 7:13524585221107095. doi: 10.1177/13524585221107095.
    PubMed     Abstract available


  304. LADAKIS DC, Yao PJ, Vreones M, Blommer J, et al
    Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis.
    Mult Scler. 2022 Jul 5:13524585221106290. doi: 10.1177/13524585221106290.
    PubMed     Abstract available


  305. MANUEL ESCOBAR J, Cortese M, Edan G, Freedman MS, et al
    Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
    Mult Scler. 2022;28:1277-1285.
    PubMed     Abstract available


  306. W KOCH M, Mostert J, Repovic P, Bowen JD, et al
    Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
    Mult Scler. 2022;28:1286-1298.
    PubMed     Abstract available


  307. ANDERSEN JB, Wandall-Holm MF, Andersen PK, Sellebjerg F, et al
    Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort.
    Mult Scler. 2022;28:1239-1247.
    PubMed     Abstract available


  308. GIOVANNONI G, Singer BA, Issard D, Jack D, et al
    Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Mult Scler. 2022;28:1219-1228.
    PubMed     Abstract available


  309. EISELE P, Wittayer M, Weber CE, Platten M, et al
    Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
    Mult Scler. 2022 Jul 1:13524585221106338. doi: 10.1177/13524585221106338.
    PubMed     Abstract available


    June 2022
  310. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    PubMed     Abstract available


  311. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    PubMed     Abstract available


  312. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    PubMed     Abstract available


  313. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
    PubMed    


  314. HEMOND CC, Baek J, Ionete C, Reich DS, et al
    Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study.
    Mult Scler. 2022 Jun 24:13524585221102921. doi: 10.1177/13524585221102921.
    PubMed     Abstract available


  315. GARJANI A, Liu BJ, Allen CM, Gunzler DD, et al
    Decentralised clinical trials in multiple sclerosis research.
    Mult Scler. 2022 Jun 23:13524585221100401. doi: 10.1177/13524585221100401.
    PubMed     Abstract available


  316. SCHIAVETTI I, Cordioli C, Stromillo ML, Teresa Ferro M, et al
    Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
    Mult Scler. 2022 Jun 23:13524585221102918. doi: 10.1177/13524585221102918.
    PubMed     Abstract available


  317. MAAROUF A, Audoin B, Gherib S, El Mendili MM, et al
    Grey-matter sodium concentration as an individual marker of multiple sclerosis severity.
    Mult Scler. 2022 Jun 20:13524585221102587. doi: 10.1177/13524585221102587.
    PubMed     Abstract available


  318. LAZZAROTTO A, Tonietto M, Poirion E, Battaglini M, et al
    Clinically relevant profiles of myelin content changes in patients with multiple sclerosis: A multimodal and multicompartment imaging study.
    Mult Scler. 2022 Jun 16:13524585221096975. doi: 10.1177/13524585221096975.
    PubMed     Abstract available


  319. CHO EB, Yeo Y, Jung JH, Jeong SM, et al
    Acute myocardial infarction risk in multiple sclerosis and neuromyelitis optica spectrum disorder: A nationwide cohort study in South Korea.
    Mult Scler. 2022 Jun 13:13524585221096964. doi: 10.1177/13524585221096964.
    PubMed     Abstract available


  320. AL-LOUZI O, Manukyan S, Donadieu M, Absinta M, et al
    Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.
    Mult Scler. 2022 Jun 8:13524585221097560. doi: 10.1177/13524585221097560.
    PubMed     Abstract available


  321. SCHMIERER K, Wiendl H, Oreja-Guevara C, Centonze D, et al
    Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
    Mult Scler. 2022 Jun 7:13524585221099413. doi: 10.1177/13524585221099413.
    PubMed    


  322. BRUNE S, Hogestol EA, de Rodez Benavent SA, Berg-Hansen P, et al
    Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221097296. doi: 10.1177/13524585221097296.
    PubMed     Abstract available


  323. LEAVITT VM, Dworkin JD, Buyukturkoglu K, Riley CS, et al
    Summary metrics of memory subnetwork functional connectivity alterations in multiple sclerosis.
    Mult Scler. 2022 Jun 4:13524585221099169. doi: 10.1177/13524585221099169.
    PubMed     Abstract available


  324. BEREK K, Hegen H, Hocher J, Auer M, et al
    Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.
    Mult Scler. 2022 Jun 2:13524585221097566. doi: 10.1177/13524585221097566.
    PubMed     Abstract available


  325. CARCAMO C, Ciampi E
    Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
    Mult Scler. 2022;28:1032-1033.
    PubMed    


  326. PIEHL F, Mathew T
    Low-dose rituximab should be used for treating MS in resource-limited settings: Yes.
    Mult Scler. 2022;28:1028-1029.
    PubMed    


  327. MATEEN FJ
    Low-dose rituximab should be used for treating MS in resource-limited settings: No.
    Mult Scler. 2022;28:1030-1032.
    PubMed    


  328. PODDA J, Tacchino A, Pedulla L, Monti Bragadin M, et al
    Focus on neglected features of cognitive rehabilitation in MS: Setting and mode of the treatment.
    Mult Scler. 2022;28:1009-1019.
    PubMed     Abstract available


    May 2022
  329. COFRE LIZAMA LE, Strik M, Van der Walt A, Kilpatrick TJ, et al
    Gait stability reflects motor tracts damage at early stages of multiple sclerosis.
    Mult Scler. 2022 May 21:13524585221094464. doi: 10.1177/13524585221094464.
    PubMed     Abstract available


  330. FADDA G, Waters P, Woodhall M, Brown RA, et al
    Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria.
    Mult Scler. 2022 May 17:13524585221093789. doi: 10.1177/13524585221093789.
    PubMed     Abstract available


  331. GONZALEZ-MARTINEZ A, Bose G, Chitnis T
    Anti-CGRP therapies for migraine in multiple sclerosis patients.
    Mult Scler. 2022 May 14:13524585221096353. doi: 10.1177/13524585221096353.
    PubMed    


  332. SCHWARZ T, Otto C, Jones TC, Pache F, et al
    Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
    Mult Scler. 2022 May 14:13524585221094478. doi: 10.1177/13524585221094478.
    PubMed     Abstract available


  333. LEUNG MW, Bazelier MT, Souverein PC, Uitdehaag BM, et al
    Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum.
    Mult Scler. 2022 May 14:13524585221094218. doi: 10.1177/13524585221094218.
    PubMed     Abstract available


  334. ALMRAMHI MM, Storm CS, Kia DA, Coneys R, et al
    The role of body fat in multiple sclerosis susceptibility and severity: A Mendelian randomisation study.
    Mult Scler. 2022 May 14:13524585221092644. doi: 10.1177/13524585221092644.
    PubMed     Abstract available


  335. CHIARAVALLOTI ND, DeLuca J, Salter A, Amato MP, et al
    The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Mult Scler. 2022 May 9:13524585221088190. doi: 10.1177/13524585221088190.
    PubMed     Abstract available


  336. MANGLANI HR, Fisher ME, Duraney EJ, Nicholas JA, et al
    A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures.
    Mult Scler. 2022 May 9:13524585221088731. doi: 10.1177/13524585221088731.
    PubMed     Abstract available


  337. VALSASINA P, Gobbi C, Zecca C, Rovira A, et al
    Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis.
    Mult Scler. 2022;28:885-899.
    PubMed     Abstract available


  338. ROSENSTEIN I, Axelsson M, Novakova L, Blennow K, et al
    Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study.
    Mult Scler. 2022;28:872-884.
    PubMed     Abstract available



  339. ACTRIMS Forum 2022.
    Mult Scler. 2022;28.
    PubMed    


    April 2022
  340. SPRENGER T, Kappos L, Sormani MP, Miller AE, et al
    Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
    Mult Scler. 2022 Apr 29:13524585221089534. doi: 10.1177/13524585221089534.
    PubMed     Abstract available


  341. DEGRAEVE B, Sequeira H, Mecheri H, Lenne B, et al
    Corpus callosum damage to account for cognitive, affective, and social-cognitive dysfunctions in multiple sclerosis: A model of callosal disconnection syndrome?
    Mult Scler. 2022 Apr 27:13524585221091067. doi: 10.1177/13524585221091067.
    PubMed     Abstract available


  342. MANZANO GS, Rice DR, Klawiter EC, Matiello M, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Apr 27:13524585221092309. doi: 10.1177/13524585221092309.
    PubMed     Abstract available


  343. ZABALZA A, Arrambide G, Otero-Romero S, Pappolla A, et al
    Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
    Mult Scler. 2022 Apr 27:13524585221089540. doi: 10.1177/13524585221089540.
    PubMed     Abstract available


  344. SIMONEAU G, Pellegrini F, Debray TP, Rouette J, et al
    Recommendations for the use of propensity score methods in multiple sclerosis research.
    Mult Scler. 2022 Apr 6:13524585221085733. doi: 10.1177/13524585221085733.
    PubMed     Abstract available


  345. CREE BA, Arnold DL, Fox RJ, Gold R, et al
    Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Mult Scler. 2022 Apr 5:13524585221083194. doi: 10.1177/13524585221083194.
    PubMed     Abstract available


  346. KALINCIK T, Kister I, Bacon TE, Malpas CB, et al
    Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
    Mult Scler. 2022 Apr 3:13524585221084577. doi: 10.1177/13524585221084577.
    PubMed     Abstract available


  347. MOCCIA M, Affinito G, Ronga B, Giordana R, et al
    Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).
    Mult Scler. 2022;28:597-607.
    PubMed     Abstract available


  348. GRATCH D, Zhovtis Ryerson L
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
    Mult Scler. 2022;28:695-696.
    PubMed    


  349. INES CIPLEA A, Kurzeja A, Thiel S, Haben S, et al
    Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.
    Mult Scler. 2022 Apr 1:13524585221083982. doi: 10.1177/13524585221083982.
    PubMed     Abstract available


  350. TZANETAKOS D, Tzartos JS, Vakrakou AG, Breza M, et al
    Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study.
    Mult Scler. 2022;28:718-729.
    PubMed     Abstract available


  351. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter.
    Mult Scler. 2022;28:697-706.
    PubMed     Abstract available


  352. KIM KH, Kim SH, Park NY, Hyun JW, et al
    Reappraisal of CSF-specific oligoclonal bands in Asia.
    Mult Scler. 2022;28:665-668.
    PubMed     Abstract available


  353. KUHLE J, Daizadeh N, Benkert P, Maceski A, et al
    Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
    Mult Scler. 2022;28:573-582.
    PubMed     Abstract available


  354. BAJRAMI A, Magliozzi R, Pisani AI, Pizzini FB, et al
    Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS.
    Mult Scler. 2022;28:550-560.
    PubMed     Abstract available


  355. VALENTINE TR, Alschuler KN, Ehde DM, Kratz AL, et al
    Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis.
    Mult Scler. 2022;28:620-631.
    PubMed     Abstract available


    March 2022
  356. GASPERI C, Hapfelmeier A, Schneider A, Kuhn KA, et al
    Association of pregnancies with risk of multiple sclerosis.
    Mult Scler. 2022 Mar 18:13524585221080542. doi: 10.1177/13524585221080542.
    PubMed     Abstract available


  357. PORTACCIO E, Pasto L, Razzolini L, Moiola L, et al
    Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Mult Scler. 2022 Mar 16:13524585221079598. doi: 10.1177/13524585221079598.
    PubMed     Abstract available


  358. RIEMENSCHNEIDER M, Hvid LG, Ringgaard S, Nygaard MKE, et al
    Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
    Mult Scler. 2022 Mar 16:13524585221079200. doi: 10.1177/13524585221079200.
    PubMed     Abstract available


  359. CARLSON A, McGinley MP
    Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.
    Mult Scler. 2022 Mar 16:13524585221081985. doi: 10.1177/13524585221081985.
    PubMed    


  360. LIANG G, Zhu F, Mirza AI, Bar-Or A, et al
    Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases.
    Mult Scler. 2022 Mar 16:13524585221079533. doi: 10.1177/13524585221079533.
    PubMed     Abstract available


  361. JACOBS BM, Watson C, Marshall C, Noyce A, et al
    No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 16:13524585221075744. doi: 10.1177/13524585221075744.
    PubMed    


  362. DALGAS U, Stenager E, Hvid LG
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: Commentary.
    Mult Scler. 2022 Mar 16:13524585211072702. doi: 10.1177/13524585211072702.
    PubMed    


  363. MOTL RW, Sandroff BM
    Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect-Yes.
    Mult Scler. 2022 Mar 16:13524585211061651. doi: 10.1177/13524585211061651.
    PubMed    


  364. HEESEN C, Rosenkranz SC
    Physical exercise in multiple sclerosis is not just a symptomatic therapy, it has a disease-modifying effect: No.
    Mult Scler. 2022 Mar 16:13524585211064968. doi: 10.1177/13524585211064968.
    PubMed    


  365. WENDEL EM, Bertolini A, Kousoulos L, Rauchenzauner M, et al
    Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome.
    Mult Scler. 2022 Mar 14:13524585221081090. doi: 10.1177/13524585221081090.
    PubMed     Abstract available


  366. BSTEH G, Hegen H, Berek K, Altmann P, et al
    Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
    Mult Scler. 2022 Mar 12:13524585221079744. doi: 10.1177/13524585221079744.
    PubMed     Abstract available


  367. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants.
    Mult Scler. 2022 Mar 12:13524585221079044. doi: 10.1177/13524585221079044.
    PubMed    


  368. GARTNER J, Hauser SL, Bar-Or A, Montalban X, et al
    Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
    Mult Scler. 2022 Mar 10:13524585221078825. doi: 10.1177/13524585221078825.
    PubMed     Abstract available


  369. ARNOLD DL, Piani-Meier D, Bar-Or A, Benedict RH, et al
    Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Mult Scler. 2022 Mar 9:13524585221076717. doi: 10.1177/13524585221076717.
    PubMed     Abstract available


  370. BEBO BF JR, Allegretta M, Landsman D, Zackowski KM, et al
    Pathways to cures for multiple sclerosis: A research roadmap.
    Mult Scler. 2022;28:331-345.
    PubMed     Abstract available


  371. HAUSER SL, Cross AH, Winthrop K, Wiendl H, et al
    Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
    Mult Scler. 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
    PubMed     Abstract available


  372. PORTACCIO E, Tudisco L, Pasto L, Razzolini L, et al
    Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
    Mult Scler. 2022;28:472-479.
    PubMed     Abstract available


  373. VAVASOUR IM, Sun P, Graf C, Yik JT, et al
    Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging.
    Mult Scler. 2022;28:418-428.
    PubMed     Abstract available


    February 2022
  374. TUR C, Dubessy AL, Otero-Romero S, Amato MP, et al
    The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Mult Scler. 2022 Feb 23:13524585211069068. doi: 10.1177/13524585211069068.
    PubMed     Abstract available


  375. SHAFIN N, Ismail CAN, Mustafa MZ, Ghani N, et al
    Thematic analysis of multiple sclerosis research by enhanced strategic diagram.
    Mult Scler. 2022 Feb 15:13524585221075542. doi: 10.1177/13524585221075542.
    PubMed     Abstract available



  376. Erratum to "Assessing diagnosis disclosure and concealment in multiple sclerosis: building a framework for moving forward".
    Mult Scler. 2022 Feb 11:13524585221079450. doi: 10.1177/13524585221079450.
    PubMed    


  377. BECK ES, Maranzano J, Luciano NJ, Parvathaneni P, et al
    Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis.
    Mult Scler. 2022 Feb 10:13524585211069167. doi: 10.1177/13524585211069167.
    PubMed     Abstract available


  378. RODRIGUEZ LLORIAN E, Zhang W, Khakban A, Patten S, et al
    Productivity loss among people with early multiple sclerosis: A Canadian study.
    Mult Scler. 2022 Feb 9:13524585211069070. doi: 10.1177/13524585211069070.
    PubMed     Abstract available


  379. O'MAHONY J, Banwell B, Laporte A, Brown A, et al
    The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents.
    Mult Scler. 2022 Feb 7:13524585211061521. doi: 10.1177/13524585211061521.
    PubMed     Abstract available


  380. HOLM HANSEN R, Hojsgaard Chow H, Talbot J, Buhelt S, et al
    Peripheral helper T cells in the pathogenesis of multiple sclerosis.
    Mult Scler. 2022 Feb 3:13524585211067696. doi: 10.1177/13524585211067696.
    PubMed     Abstract available


  381. DOBSON R, Chung K
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary.
    Mult Scler. 2022;28:326-327.
    PubMed    


  382. COYLE PK, Syritsyna O
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Yes.
    Mult Scler. 2022;28:183-185.
    PubMed    


  383. BERMEL RA
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - No.
    Mult Scler. 2022;28:185-187.
    PubMed    


  384. FOX RJ, Tintore M
    DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity - Commentary.
    Mult Scler. 2022;28:187-188.
    PubMed    


  385. HILLERT J, Tsai JA, Nouhi M, Glaser A, et al
    A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
    Mult Scler. 2022;28:237-246.
    PubMed     Abstract available


  386. ZHENG Y, Dudman J, Chen JT, Mahajan KR, et al
    Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI.
    Mult Scler. 2022;28:198-205.
    PubMed     Abstract available


  387. PFEUFFER S, Rolfes L, Hackert J, Kleinschnitz K, et al
    Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
    Mult Scler. 2022;28:257-268.
    PubMed     Abstract available


    January 2022
  388. LIAO CM, Kuo WY, Kung PT, Chuan CH, et al
    Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan.
    Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341.
    PubMed     Abstract available


  389. NAKAMURA K, Zheng Y, Ontaneda D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes.
    Mult Scler. 2022 Jan 22:13524585211066313. doi: 10.1177/13524585211066313.
    PubMed    


  390. MUHLAU M
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No.
    Mult Scler. 2022 Jan 22:13524585211063622. doi: 10.1177/13524585211063622.
    PubMed    


  391. ROVIRA A, Pareto D
    T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary.
    Mult Scler. 2022 Jan 22:13524585211069363. doi: 10.1177/13524585211069363.
    PubMed    


  392. KEVER A, Riley CS, Leavitt VM
    Diagnosis concealment is associated with psychosocial outcomes in persons with multiple sclerosis.
    Mult Scler. 2022 Jan 16:13524585211070496. doi: 10.1177/13524585211070496.
    PubMed     Abstract available


  393. P MOSS B, Miller DM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Building a framework for moving forward.
    Mult Scler. 2022 Jan 11:13524585211069668. doi: 10.1177/13524585211069668.
    PubMed    


  394. BELVISI D, Canevelli M, Marfia GA, Ferraro E, et al
    Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework".
    Mult Scler. 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150.
    PubMed    


  395. ZIAEI A, Lavery AM, Shao XM, Adams C, et al
    Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution.
    Mult Scler. 2022 Jan 8:13524585211069926. doi: 10.1177/13524585211069926.
    PubMed     Abstract available


  396. VAN KEMPEN ZL, Hogenboom L, Killestein J
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
    Mult Scler. 2022 Jan 7:13524585211064441. doi: 10.1177/13524585211064441.
    PubMed    


  397. COHEN JA, Bermel RA, Grossman CI, Hersh CM, et al
    Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
    Mult Scler. 2022 Jan 7:13524585211061343. doi: 10.1177/13524585211061343.
    PubMed     Abstract available


  398. THOMPSON AJ, Carroll W, Ciccarelli O, Comi G, et al
    Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
    Mult Scler. 2022;28:16-28.
    PubMed     Abstract available


  399. COMABELLA M, Clarke MA, Schaedelin S, Tintore M, et al
    CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
    Mult Scler. 2022;28:71-81.
    PubMed     Abstract available


  400. SIGNORIELLO E, Lus G, Bonavita S, Lanzillo R, et al
    Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
    Mult Scler. 2022;28:93-101.
    PubMed     Abstract available


    December 2021
  401. GAITAN MI, Sanchez M, Farez MF, Fiol MP, et al
    The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina.
    Mult Scler. 2021 Dec 31:13524585211067521. doi: 10.1177/13524585211067521.
    PubMed     Abstract available


  402. BERNARDI G, Biagioli T, Malpassi P, De Michele T, et al
    The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study.
    Mult Scler. 2021 Dec 30:13524585211064121. doi: 10.1177/13524585211064121.
    PubMed     Abstract available


  403. CAVACO S, Ferreira I, Moreira I, Santos E, et al
    Cognitive dysfunction and mortality in multiple sclerosis: Long-term retrospective review.
    Mult Scler. 2021 Dec 30:13524585211066598. doi: 10.1177/13524585211066598.
    PubMed     Abstract available


  404. VAN KEMPEN ZL, Toorop AA, Sellebjerg F, Giovannoni G, et al
    Extended dosing of monoclonal antibodies in multiple sclerosis.
    Mult Scler. 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711.
    PubMed     Abstract available


  405. NG HS, Zhu F, Kingwell E, Zhao Y, et al
    Disease-modifying drugs for multiple sclerosis and subsequent health service use.
    Mult Scler. 2021 Dec 24:13524585211063403. doi: 10.1177/13524585211063403.
    PubMed     Abstract available


  406. FERNANDEZ RS, Crivelli L, Pedreira ME, Allegri RF, et al
    Computational basis of decision-making impairment in multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211059308. doi: 10.1177/13524585211059308.
    PubMed     Abstract available


  407. ZANOTTO T, Lynch SG, Hausdorff JM, Sosnoff JJ, et al
    Frailty in multiple sclerosis: A closer look at the deficit accumulation framework.
    Mult Scler. 2021 Dec 21:13524585211061332. doi: 10.1177/13524585211061332.
    PubMed    


  408. ROLFES L, Meuth SG
    Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
    Mult Scler. 2021 Dec 21:13524585211055593. doi: 10.1177/13524585211055593.
    PubMed    


  409. TOOROP AA, Rispens T, Strijbis EM, van Oosten BW, et al
    Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Mult Scler. 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168.
    PubMed     Abstract available


  410. JANUEL E, De Seze J, Vermersch P, Maillart E, et al
    Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
    Mult Scler. 2021 Dec 21:13524585211049737. doi: 10.1177/13524585211049737.
    PubMed     Abstract available


  411. COLES AJ, Jones JL, Vermersch P, Traboulsee A, et al
    Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
    Mult Scler. 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
    PubMed     Abstract available


  412. ROVIRA A, Corral JF, Auger C, Valverde S, et al
    Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients.
    Mult Scler. 2021 Dec 3:13524585211061339. doi: 10.1177/13524585211061339.
    PubMed     Abstract available


  413. LEEKOFF M, Culpepper W, Jin S, Lee-Wilk T, et al
    Impact of comorbid post traumatic stress disorder on multiple sclerosis in military veterans: A population-based cohort study.
    Mult Scler. 2021 Dec 2:13524585211058361. doi: 10.1177/13524585211058361.
    PubMed     Abstract available


  414. NOURBAKHSH B
    Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Mult Scler. 2021;27:2290.
    PubMed    


  415. LEHMANN H, Zveik O, Levin N, Brill L, et al
    Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses.
    Mult Scler. 2021;27:2232-2239.
    PubMed     Abstract available


  416. OH J, Suthiphosuwan S, Sati P, Absinta M, et al
    Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS.
    Mult Scler. 2021;27:2199-2208.
    PubMed     Abstract available


    November 2021
  417. SARKAR P, Redondo J, Hares K, Bailey S, et al
    Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection.
    Mult Scler. 2021 Nov 29:13524585211060686. doi: 10.1177/13524585211060686.
    PubMed     Abstract available


  418. OTERO-ROMERO S, Carbonell-Mirabent P, Midaglia L, Zuluaga M, et al
    Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis.
    Mult Scler. 2021 Nov 29:13524585211053001. doi: 10.1177/13524585211053001.
    PubMed     Abstract available


  419. KIRA JI, Nakahara J, Sazonov DV, Kurosawa T, et al
    Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
    Mult Scler. 2021 Nov 17:13524585211055934. doi: 10.1177/13524585211055934.
    PubMed     Abstract available


  420. SCHORR EM, Kurz D, Rossi KC, Zhang M, et al
    Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
    Mult Scler. 2021 Nov 17:13524585211051316. doi: 10.1177/13524585211051316.
    PubMed     Abstract available


  421. MARRIE RA, McKay K
    Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
    Mult Scler. 2021 Nov 17:13524585211055787. doi: 10.1177/13524585211055787.
    PubMed    


  422. MAUBEUGE N, Deloire MS, Brochet B, Charre-Morin J, et al
    Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries.
    Mult Scler. 2021 Nov 12:13524585211054006. doi: 10.1177/13524585211054006.
    PubMed     Abstract available


  423. MOUMDJIAN L, Moens B, Van Wijmeersh B, Leman M, et al
    Application of step and beat alignment approaches and its effect on gait in progressive multiple sclerosis with severe cerebellar ataxia: A proof of concept case study.
    Mult Scler. 2021 Nov 2:13524585211054000. doi: 10.1177/13524585211054000.
    PubMed     Abstract available


  424. DAHLKE F, Arnold DL, Aarden P, Ganjgahi H, et al
    Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
    Mult Scler. 2021;27:2062-2076.
    PubMed     Abstract available


    October 2021
  425. MISICKA E, Davis MF, Kim W, Brugger SW, et al
    A higher burden of multiple sclerosis genetic risk confers an earlier onset.
    Mult Scler. 2021 Oct 28:13524585211053155. doi: 10.1177/13524585211053155.
    PubMed     Abstract available


  426. PONCET-MEGEMONT L, Pereira B, Rollot F, Sormani MP, et al
    Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.
    Mult Scler. 2021 Oct 26:13524585211052400. doi: 10.1177/13524585211052400.
    PubMed     Abstract available


  427. BERGAMASCHI R, Montomoli C
    Air pollution is a risk factor for multiple sclerosis - Yes.
    Mult Scler. 2021 Oct 22:13524585211035953. doi: 10.1177/13524585211035953.
    PubMed    


  428. DELGADO-GARCIA G, Corona T
    Air pollution is a risk factor for multiple sclerosis - No.
    Mult Scler. 2021 Oct 22:13524585211026875. doi: 10.1177/13524585211026875.
    PubMed    


  429. SAHRAIAN MA
    Air pollution is a risk factor for multiple sclerosis - Commentary.
    Mult Scler. 2021 Oct 22:13524585211046352. doi: 10.1177/13524585211046352.
    PubMed    


  430. ZHONG M, van der Walt A, Stankovich J, Kalincik T, et al
    Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
    Mult Scler. 2021 Oct 8:13524585211049986. doi: 10.1177/13524585211049986.
    PubMed     Abstract available


  431. UHER T, Havrdova EK, Benkert P, Bergsland N, et al
    Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis.
    Mult Scler. 2021 Oct 6:13524585211047977. doi: 10.1177/13524585211047977.
    PubMed     Abstract available


  432. VILLOSLADA P
    Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Mult Scler. 2021 Oct 6:13524585211049552. doi: 10.1177/13524585211049552.
    PubMed    


  433. WEINSTOCK Z, Morrow S, Conway D, Fuchs T, et al
    Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Mult Scler. 2021 Oct 6:13524585211049397. doi: 10.1177/13524585211049397.
    PubMed     Abstract available


  434. SOLOMON AJ, Kaisey M, Krieger SC, Chahin S, et al
    Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States.
    Mult Scler. 2021 Oct 6:13524585211048401. doi: 10.1177/13524585211048401.
    PubMed     Abstract available


  435. BOSMA AR, Murley C, Aspling J, Hillert J, et al
    Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.
    Mult Scler. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759.
    PubMed     Abstract available


  436. BAR-OR A, Wiendl H, Montalban X, Alvarez E, et al
    Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Mult Scler. 2021 Oct 4:13524585211044479. doi: 10.1177/13524585211044479.
    PubMed     Abstract available


  437. GROTHE M, Ellenberger D, von Podewils F, Stahmann A, et al
    Epilepsy as a predictor of disease progression in multiple sclerosis.
    Mult Scler. 2021 Oct 1:13524585211046739. doi: 10.1177/13524585211046739.
    PubMed     Abstract available


  438. SANDROFF BM, Motl RW, Amato MP, Brichetto G, et al
    Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study.
    Mult Scler. 2021 Oct 1:13524585211048397. doi: 10.1177/13524585211048397.
    PubMed     Abstract available


  439. BSTEH G, Durauer S, Assar H, Hegen H, et al
    Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
    Mult Scler. 2021 Oct 1:13524585211049391. doi: 10.1177/13524585211049391.
    PubMed     Abstract available


  440. GEORGIEVA ZG, Dffinger R, Kumararatne D, Coles AJ, et al
    Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2021 Oct 1:13524585211046786. doi: 10.1177/13524585211046786.
    PubMed     Abstract available


  441. CAMERON MH, Hildebrand A, Hugos CL, Judd GI, et al
    Free From Falls education and exercise program for reducing falls in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2021 Oct 1:13524585211046898. doi: 10.1177/13524585211046898.
    PubMed     Abstract available


  442. ROBERS MV, Chan C, Vajdi B, Chiong-Rivero H, et al
    Hypertension and hypertension severity in Hispanics/Latinx with MS.
    Mult Scler. 2021;27:1894-1901.
    PubMed     Abstract available


  443. ELKJAER ML, Frisch T, Tonazzolli A, Rottger R, et al
    Unbiased examination of genome-wide human endogenous retrovirus transcripts in MS brain lesions.
    Mult Scler. 2021;27:1829-1837.
    PubMed     Abstract available


  444. KOCH MW, Mostert JP, Uitdehaag B, Cutter G, et al
    A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
    Mult Scler. 2021;27:1864-1874.
    PubMed     Abstract available


  445. KOCH MW, Metz L, Cutter G
    An enrichment strategy for clinical trials in SPMS.
    Mult Scler. 2021;27:1884-1893.
    PubMed     Abstract available


  446. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
    Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mult Scler. 2021;27:1794-1798.
    PubMed     Abstract available


  447. DE MOL CL, Bruijstens AL, Jansen PR, Dremmen M, et al
    Prevalence of radiologically isolated syndrome in a pediatric population-based cohort: A longitudinal description of a rare diagnosis.
    Mult Scler. 2021;27:1790-1793.
    PubMed     Abstract available


  448. CAPUANO R, Zubizarreta I, Alba-Arbalat S, Sepulveda M, et al
    Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
    Mult Scler. 2021;27:1706-1716.
    PubMed     Abstract available


  449. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2021;27:1643-1656.
    PubMed     Abstract available


    September 2021
  450. BUSSAS M, Grahl S, Pongratz V, Berthele A, et al
    Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Mult Scler. 2021 Sep 30:13524585211044957. doi: 10.1177/13524585211044957.
    PubMed     Abstract available


  451. KEVER A, Leavitt VM
    Assessing diagnosis disclosure and concealment in multiple sclerosis: Development and initial validation of the DISCO-MS survey.
    Mult Scler. 2021 Sep 9:13524585211037581. doi: 10.1177/13524585211037581.
    PubMed     Abstract available


  452. KRYSKO KM, Anderson A, Singh J, McPolin K, et al
    Risk factors for peripartum depression in women with multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211041108. doi: 10.1177/13524585211041108.
    PubMed     Abstract available


  453. WOJCIK C, Jaworski M 3rd, Dwyer MG, Youngs M, et al
    Benchmarks of meaningful improvement on neurocognitive tests in multiple sclerosis.
    Mult Scler. 2021 Sep 9:13524585211044672. doi: 10.1177/13524585211044672.
    PubMed     Abstract available


  454. TREMLETT H, Okuda DT, Lebrun-Frenay C
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
    Mult Scler. 2021 Sep 8:13524585211035951. doi: 10.1177/13524585211035951.
    PubMed    


  455. GNANAPAVAN S
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Yes.
    Mult Scler. 2021 Sep 8:13524585211040223. doi: 10.1177/13524585211040223.
    PubMed    


  456. MAKHANI N
    The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - Commentary.
    Mult Scler. 2021 Sep 8:13524585211044951. doi: 10.1177/13524585211044951.
    PubMed    


  457. BRADLEY L
    Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Mult Scler. 2021 Sep 5:13524585211035737. doi: 10.1177/13524585211035737.
    PubMed     Abstract available


  458. ENZINGER C
    Slowly expanding lesions are a marker of progressive multiple sclerosis - Commentary.
    Mult Scler. 2021 Sep 3:13524585211040225. doi: 10.1177/13524585211040225.
    PubMed    


  459. HARTUNG HP, Meuth SG, Thompson AJ
    Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis.
    Mult Scler. 2021;27:1473-1476.
    PubMed    


  460. GOLD R, Arnold DL, Bar-Or A, Fox RJ, et al
    Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Mult Scler. 2021 Sep 1:13524585211037909. doi: 10.1177/13524585211037909.
    PubMed     Abstract available


  461. IAFFALDANO P, Lucisano G, Butzkueven H, Hillert J, et al
    Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
    Mult Scler. 2021;27:1543-1555.
    PubMed     Abstract available


  462. DALLA COSTA G, Croese T, Pisa M, Finardi A, et al
    CSF extracellular vesicles and risk of disease activity after a first demyelinating event.
    Mult Scler. 2021;27:1606-1610.
    PubMed     Abstract available


  463. SCHNEIDER-HOHENDORF T, Schulte-Mecklenbeck A, Ostkamp P, Janoschka C, et al
    High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients.
    Mult Scler. 2021;27:1491-1496.
    PubMed     Abstract available


  464. COHEN M, Mondot L, Bucciarelli F, Pignolet B, et al
    BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
    Mult Scler. 2021;27:1556-1563.
    PubMed     Abstract available


  465. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2021;27:1477-1485.
    PubMed     Abstract available


    August 2021
  466. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
    PubMed    


  467. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    PubMed     Abstract available


  468. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    PubMed     Abstract available


  469. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    PubMed     Abstract available


  470. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
    PubMed    


  471. ABBADESSA G, Lavorgna L, Treaba CA, Bonavita S, et al
    Hemostatic factors in the pathogenesis of neuroinflammation in multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039111. doi: 10.1177/13524585211039111.
    PubMed     Abstract available


  472. BUTLER PAGNOTTI R, Hua LH, Miller JB
    Cognition and disease characteristics in adult onset versus late onset multiple sclerosis.
    Mult Scler. 2021 Aug 19:13524585211039112. doi: 10.1177/13524585211039112.
    PubMed     Abstract available


  473. TILLAUT H, Degremont A, Kerbrat S, Roux J, et al
    Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies.
    Mult Scler. 2021 Aug 19:13524585211035376. doi: 10.1177/13524585211035376.
    PubMed     Abstract available


  474. ROMMER PS, Bsteh G, Berger T, Zettl UK, et al
    SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
    Mult Scler. 2021 Aug 13:13524585211039128. doi: 10.1177/13524585211039128.
    PubMed    


  475. MARCHESI O, Bonacchi R, Valsasina P, Preziosa P, et al
    Functional and structural MRI correlates of executive functions in multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211033184. doi: 10.1177/13524585211033184.
    PubMed     Abstract available


  476. CLAFLIN SB, Campbell JA, Mason DF, Kalincik T, et al
    The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
    Mult Scler. 2021 Aug 13:13524585211035948. doi: 10.1177/13524585211035948.
    PubMed     Abstract available


  477. WEINSTOCK-GUTTMAN B, Bermel R, Cutter G, Freedman MS, et al
    Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
    Mult Scler. 2021 Aug 12:13524585211035740. doi: 10.1177/13524585211035740.
    PubMed     Abstract available


  478. DE MOL CL, Neuteboom RF, Jansen PR, White T, et al
    White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study.
    Mult Scler. 2021 Aug 11:13524585211034826. doi: 10.1177/13524585211034826.
    PubMed     Abstract available


  479. AYADI N, Oertel FC, Asseyer S, Rust R, et al
    Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2021 Aug 11:13524585211032801. doi: 10.1177/13524585211032801.
    PubMed     Abstract available


  480. ZHENG F, Li Y, Zhuo Z, Duan Y, et al
    Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Mult Scler. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800.
    PubMed     Abstract available


  481. COMI G, Dadon Y, Sasson N, Steinerman JR, et al
    CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Aug 11:13524585211032803. doi: 10.1177/13524585211032803.
    PubMed     Abstract available


  482. PANDIT L
    Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines.
    Mult Scler. 2021;27:1320-1322.
    PubMed    


  483. KANINIA S, Grammatikos A, Urankar K, Renowden SA, et al
    CNS demyelination associated with immune dysregulation and a novel CTLA-4 variant.
    Mult Scler. 2021;27:1464-1467.
    PubMed     Abstract available


  484. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2021;27:1323-1331.
    PubMed     Abstract available


    July 2021
  485. SORMANI MP, Schiavetti I, Landi D, Carmisciano L, et al
    SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
    Mult Scler. 2021 Jul 30:13524585211035318. doi: 10.1177/13524585211035318.
    PubMed     Abstract available


  486. ROTSTEIN D, Maxwell C, Tu K, Gatley J, et al
    High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis.
    Mult Scler. 2021 Jul 30:13524585211031791. doi: 10.1177/13524585211031791.
    PubMed     Abstract available


  487. PITTERI M, Magliozzi R, Nicholas R, Ziccardi S, et al
    Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients.
    Mult Scler. 2021 Jul 30:13524585211032510. doi: 10.1177/13524585211032510.
    PubMed     Abstract available


  488. UHR L, Mateen FJ
    COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey.
    Mult Scler. 2021 Jul 27:13524585211030647. doi: 10.1177/13524585211030647.
    PubMed     Abstract available


  489. LAURSON-DOUBE J, Rijke N, Helme A, Baneke P, et al
    Ethical use of off-label disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211030207. doi: 10.1177/13524585211030207.
    PubMed     Abstract available


  490. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
    Mult Scler. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801.
    PubMed     Abstract available


  491. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available


  492. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available


  493. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available


  494. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available


  495. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    PubMed    


  496. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available


  497. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available


  498. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available


  499. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available


  500. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available


  501. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    PubMed    


  502. CALDITO NG, O'Leary S, Stuve O
    Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Mult Scler. 2021;27:1306-1308.
    PubMed     Abstract available


  503. MARRIE RA, Patel R, Bernstein CN, Bolton JM, et al
    Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.
    Mult Scler. 2021;27:1284-1292.
    PubMed     Abstract available


  504. CENCIONI MT, Ali R, Nicholas R, Muraro PA, et al
    Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS.
    Mult Scler. 2021;27:1187-1197.
    PubMed     Abstract available


    June 2021
  505. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available


  506. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available


  507. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available


  508. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available


  509. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available


  510. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available


  511. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available


  512. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available


  513. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available


  514. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available


  515. SCHMIERER K, Giovannoni G
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary.
    Mult Scler. 2021;27:1006-1007.
    PubMed    


  516. SCALFARI A
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes.
    Mult Scler. 2021;27:1002-1004.
    PubMed    


  517. CROSS AH, Naismith RT
    MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No.
    Mult Scler. 2021;27:1004-1005.
    PubMed    


  518. ZACKOWSKI KM, Freeman J, Brichetto G, Centonze D, et al
    Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance.
    Mult Scler. 2021;27:989-1001.
    PubMed     Abstract available


  519. MORROW SA, Conway D, Fuchs T, Wojcik C, et al
    Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses.
    Mult Scler. 2021;27:1077-1087.
    PubMed     Abstract available


  520. NAYAK S, Sechi E, Flanagan EP, Messina S, et al
    Inflammatory activity following motor progression due to critical CNS demyelinating lesions.
    Mult Scler. 2021;27:1037-1045.
    PubMed     Abstract available


  521. REDER AT
    Thoracic flexion provokes circumferential dysesthesia: A symptom of thoracic cord lesions in MS.
    Mult Scler. 2021;27:1008-1013.
    PubMed     Abstract available


    May 2021
  522. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available


  523. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available


  524. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available


  525. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed    


  526. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed    


  527. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed    


  528. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available


  529. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available


  530. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available


  531. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available


  532. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    PubMed    


  533. LONGBRAKE EE, Mao-Draayer Y, Cascione M, Zielinski T, et al
    Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Mult Scler. 2021;27:883-894.
    PubMed     Abstract available


  534. CAI MT, Zheng Y, Shen CH, Yang F, et al
    Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Mult Scler. 2021;27:871-882.
    PubMed     Abstract available


  535. KASSA RM, Sechi E, Flanagan EP, Kaufmann TJ, et al
    Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions.
    Mult Scler. 2021;27:895-902.
    PubMed     Abstract available


    April 2021
  536. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available


  537. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available


  538. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available


  539. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available


  540. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available


  541. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available


  542. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available


  543. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available


  544. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available


  545. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available


  546. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available


  547. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available


  548. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available


  549. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available


  550. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available


  551. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available


  552. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available


  553. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed     Abstract available


  554. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    PubMed    


  555. MANCINELLI CR, Scarpazza C, Cordioli C, De Rossi N, et al
    Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mult Scler. 2021;27:790-794.
    PubMed     Abstract available


  556. BIGAUT K, Fabacher T, Kremer L, Ongagna JC, et al
    Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
    Mult Scler. 2021;27:729-741.
    PubMed     Abstract available


  557. KUNCHOK A, Lechner-Scott J, Granella F, Trojano M, et al
    Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
    Mult Scler. 2021;27:695-705.
    PubMed     Abstract available


  558. SECHI E, Messina S, Keegan BM, Buciuc M, et al
    Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study.
    Mult Scler. 2021;27:667-673.
    PubMed     Abstract available


  559. DATTA P, Ciplea AI, Rewers-Felkins K, Baker T, et al
    Cladribine transfer into human milk: A case report.
    Mult Scler. 2021;27:799-801.
    PubMed     Abstract available


    March 2021
  560. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    PubMed     Abstract available


  561. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    PubMed     Abstract available


  562. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    PubMed     Abstract available


  563. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    PubMed     Abstract available


  564. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    PubMed     Abstract available


  565. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    PubMed     Abstract available


  566. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed     Abstract available


  567. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    PubMed     Abstract available


  568. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    PubMed     Abstract available


  569. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    PubMed     Abstract available


  570. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    PubMed    


  571. BUTZKUEVEN H, Trojano M, Kappos L, Spelman T, et al
    Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP).
    Mult Scler. 2021;27:410-419.
    PubMed     Abstract available


    February 2021
  572. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed     Abstract available


  573. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    PubMed     Abstract available


  574. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    PubMed    


  575. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    PubMed     Abstract available


  576. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    PubMed     Abstract available


  577. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    PubMed     Abstract available


  578. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    PubMed     Abstract available


  579. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    PubMed     Abstract available


  580. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed     Abstract available


  581. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed     Abstract available


  582. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed     Abstract available


  583. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed     Abstract available


  584. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed     Abstract available



  585. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    PubMed     Abstract available


  586. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    PubMed     Abstract available


  587. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed    


  588. SALTER A, Stahmann A, Ellenberger D, Fneish F, et al
    Data harmonization for collaborative research among MS registries: A case study in employment.
    Mult Scler. 2021;27:281-289.
    PubMed     Abstract available


    January 2021
  589. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    PubMed     Abstract available


  590. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    PubMed     Abstract available


  591. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    PubMed     Abstract available


  592. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    PubMed     Abstract available


  593. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    PubMed     Abstract available


  594. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    PubMed    


  595. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    PubMed    


  596. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    PubMed    


  597. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    PubMed     Abstract available


  598. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    PubMed     Abstract available


  599. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    PubMed    


  600. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed    


  601. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed     Abstract available


  602. LIBERTINOVA J, Meluzinova E, Nema E, Rockova P, et al
    Elevated D-dimer as an immediate response to alemtuzumab treatment.
    Mult Scler. 2021;27:151-154.
    PubMed     Abstract available


  603. ZHANG J, Giorgio A, Vinciguerra C, Stromillo ML, et al
    Gray matter atrophy cannot be fully explained by white matter damage in patients with MS.
    Mult Scler. 2021;27:39-51.
    PubMed     Abstract available


  604. GEORGE IC, El Mendili MM, Inglese M, Azevedo CJ, et al
    Cerebellar volume loss in radiologically isolated syndrome.
    Mult Scler. 2021;27:130-133.
    PubMed     Abstract available


    December 2020
  605. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    PubMed     Abstract available


  606. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    PubMed    


  607. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    PubMed    


  608. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    PubMed    


  609. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    PubMed     Abstract available


  610. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    PubMed    


  611. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    PubMed    


  612. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    PubMed    


  613. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    PubMed     Abstract available


  614. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available


  615. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    PubMed     Abstract available


  616. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    PubMed     Abstract available


  617. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    PubMed     Abstract available


  618. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    PubMed    


  619. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    PubMed    


  620. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    PubMed     Abstract available


  621. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    PubMed     Abstract available


  622. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    PubMed     Abstract available


  623. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    PubMed    


  624. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    PubMed    


  625. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    PubMed    


    November 2020
  626. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    PubMed     Abstract available


  627. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    PubMed     Abstract available


  628. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    PubMed     Abstract available


  629. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    PubMed     Abstract available


  630. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    PubMed     Abstract available


  631. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    PubMed     Abstract available


  632. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    PubMed     Abstract available


  633. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    PubMed     Abstract available


  634. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    PubMed     Abstract available


  635. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    PubMed     Abstract available


  636. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    PubMed     Abstract available


  637. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    PubMed     Abstract available


  638. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    PubMed     Abstract available


  639. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    PubMed     Abstract available


  640. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    PubMed     Abstract available


  641. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    PubMed     Abstract available


  642. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    PubMed     Abstract available


    October 2020
  643. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    PubMed     Abstract available


  644. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    PubMed     Abstract available


  645. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    PubMed     Abstract available


  646. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    PubMed     Abstract available


  647. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    PubMed     Abstract available


  648. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    PubMed    


  649. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    PubMed    


  650. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    PubMed     Abstract available


  651. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    PubMed     Abstract available


  652. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    PubMed     Abstract available


  653. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    PubMed     Abstract available


  654. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    PubMed     Abstract available


  655. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    PubMed     Abstract available


  656. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    PubMed    


  657. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    PubMed    


  658. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    PubMed    


    September 2020
  659. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    PubMed     Abstract available


  660. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    PubMed     Abstract available


  661. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    PubMed     Abstract available


  662. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    PubMed     Abstract available


  663. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    PubMed    


  664. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    PubMed    


    August 2020
  665. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    PubMed    


    June 2020

  666. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    PubMed     Abstract available


  667. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed     Abstract available


    May 2020
  668. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


    March 2020
  669. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available


  670. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed    


  671. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed    


  672. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed     Abstract available


  673. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed     Abstract available


    February 2020
  674. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available


  675. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    PubMed    


  676. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    PubMed    


  677. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    PubMed    


  678. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    PubMed    


    January 2020
  679. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    PubMed    


  680. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    PubMed    


  681. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    PubMed     Abstract available


  682. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    PubMed     Abstract available


    November 2019
  683. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available


  684. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available


    June 2019
  685. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available


    March 2019
  686. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed     Abstract available


    February 2019
  687. CUKER A, Bass AD, Nadj C, Agius MA, et al
    Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.